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ABSTRACT

Investigation of the biological basis of anxiety is hampered by the lack of an appropriate animal model for research
purposes.

There are no known drugs that cause anxiety in

laboratory animals.

Pentylenetetrazol (PTZ) produces intense

anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun,
1970).

Therefore, it was the major objective of this disser-

tation to test the hypothesis that the discriminative stimulus produced by PTZ in the rat was related to its anxiogenic
action in man.

It was also an objective to suggest the neuro-

chemical basis for the discriminative stimulus property of
PTZ through appropriate drug interactions.

In an operant pro-

cedure of lever pressing on a FR 10 schedule of food reinforcement, male hooded rats were trained to respond with a
lever on one side of a food cup 15 min following a 20 mg/kg
PTZ injection and to respond with a lever on the alternate
side 15 min following a 1 ml/kg saline injection.

All of

the rats learned this discrimination reliably in a mean of 30
training sessions.

The discriminative stimulus produced by

PTZ was dose- and time-dependent.

The anxiogenic stimulants

cocaine, R05-3663 and strychnine generalized to the PTZ discriminative stimulus whereas yohimbine partially generalized.
The discriminative stimulus produced by cocaine, R05-3663
and yohimbine was antagonized by the anxiolytic drug, diazepam.

The discriminative stimulus produced by cocaine was not antagonized by haloperidol.
lants

~-amphetamine,

eralize to

~he

The non-anxiogenic psychomotor stimu-

methylphenidate or caffeine did not gen-

PTZ discriminative stimulus.

Bemegride was

the only convulsant drug tested that generalized to the PTZ
discriminative stimulus.

Picrotoxin and 3-mercaptopropionic

partially, but not significantly, generalized to the PTZ discriminative stimulus but bicuculline, garnma-hydroxybutyrate
or nicotine did not generalize.

The PTZ discriminative stim-

ulus was dose-dependently antagonized by benzodiazepine-type,
barbiturate-type, propanediol carbamate-type anxiolytics as
well as valproic acid.

Tolerance did not develop to antago-

nism of the PTZ of discriminative stimulus by diazepam or
chlordiazepoxide.

The discriminative stiIT'ulus produced by

PTZ was not antagonized by an anticonvulsant or other central
nervous system depressants that are not anxiolytics.

There

was a significant correlation between the potency of drugs
effective in antagonizing the PTZ discriminative stimulus
and their effective doses in a conflict test of anxiety as
well as their clinically effective doses.

The GABA antago-

nist ROS-3663 generalized to the PTZ discriminative stimulus
whereas picrotoxin and 3-mercaptopropionic acid partially
generalized.

The PTZ discriminative stimulus was antagonized

by the GABA mimetic, valproic acid.

The glycine antagonist,

strychnine, generalized to the PTZ discriminative stimulus.
Neither acetylcholine nor serotonin agonists or antagonists

generalized to or antagonized the PTZ discriminative stimulus.
The catecholamine agonist, cocaine, generalized to the PTZ
discri~inative

stimulus whereas yohimbine and apomorphine par-

tially generalized.

However, neither a-amphetamine nor methyl-

phenidate generalized to the PTZ discriminative stimulus and
catecholamine receptor antagonists did not antagonize the PTZ
discriminative stimulus.

Generalization to the PTZ discrimi-

native stimulus by anxiogenic drugs and lack of generalization
by non-anxiogenic psychomotor stimulants or convulsants as
well as antagonism of the PTZ discriminative stimulus by anxiolytics but not non-anxiolytic anticonvulsant or depressants
supports the hypothesis that the discriminative stimulus produced by PTZ in the rat is related to its anxiogenic action
in man.

Generalization to the PTZ discriminative stimulus by

GABA antagonists and antagonism by GABA agonists but lack of
generalization to or antagonism by drugs affecting other neurotransmitter systems suggests that the PTZ discriminative
stimulus might be ·mediated through decreased GABA neuronal activity.
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INTRODUCTION
Anxiety is an unpleasant emotion for which millions of
patients visit physicians each year seeking relief (Rickels
et al., 1978).

Anxiety can be defined as that experience or

feeling of an unpleasantness or impending doom (Matz and
Nash, 1979).
Although we suffer from and can define anxiety we do not
understand its biological basis.

This is partly because in-

vestigations of the biological basis of anxiety have been
hampered by the lack of an appropriate animal model for research purposes.

Presently, conflict paradigms such as those

described by Geller and Seifter (1962) and Howard and Pollard
(1977) are believed to provide the best animal models of anxiety.

These procedures have been used to investigate the

biological basis of anxiety as well as the neurochemical mechanisms underlying the anxiolytic action of anti-anxiety drugs
(for reviews see Sepinwall and Cook, 19 7 8; Lippa ·et al., 19 79) .
However, with regard to elucidating the biological basis of
anxiety these studies have not met with great success.

In

addition, conflict procedures are not without methodological
problems that make interpretation of results difficult
(Howard and Pollard, 1977) .

Therefore, a more appropriate

animal model to investigate the biological basis of anxiety
is needed.
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Pentylenetetrazol (PTZ) has been reported to produce intense anxiety in human volunteers (Rodin, 1958; Rodin and
Calhou~,

1970).

In a personal communication, Rodin wrote

" ... within a matter of seconds [(after he had had himself injected with the drug by another physician)]
catastrophic anxiety ...
impending catastrophe.

I experienced

It was a sense of utter distress and
There is no doubt that this was one

of the most anxiety producing events of my life."
Subjective effects of drugs cannot be measured directly
in laboratory aniITals, however, it is believed that these effects are reflected in the discriminative stimulus properties
of drugs in a number of cases (for review see Lal, 1977;
Schuster and Balster, 1977; Colpaert and Rosecrans, 1978).
Therefore it was the major objective of this dissertation to
test the hypothesis that the discriminative stimulus produced by PTZ in the rat was related to its anxiogenic action
in humans.

It was also an objective to suggest a neurochemi-

cal basis of the discriminative stimulus property of PTZ in
the rat.
It was hoped that characterization of the anxiomimetic
property of PTZ in the rat utilizing the drug discrimination
paradigm would provide a more appropriate animal model to investigate the biological basis of anxiety.
This research problem is of significance because it
could contribute towards a better understanding of the biological basis of anxiety which could result in the development of better treatments for this unpleasant emotion.

LITERATURE REVIEW

BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF PTZ

A.Behavioral Actions of PTZ
Most of the research to date on the behavioral actions
of PTZ have been concerned with the effect of this drug on
learning and memory.

This section of the literature review

will therefore concentrate on the effect of PTZ on these behaviors.

Facilitation of Learning
Several investigators have reported that subconvulsive
doses of PTZ facilitate learning in a variety of experimental situations.

Irwin and Benucazizi (1966) found that PTZ

(1-30 mg/kg, p.o.) significantly facilitated

one~trial

learn-

ing and memory retention of CF 1 mice in a passive avoidance
task.

This effect occurred whether PTZ was injected before

or immediately after the training trial and was greater than
that observed with strychnine or picrotoxin.
Using a simple Y maze, Hunt and Krivanek (1966) and
Krivanek and Hunt (1967) reported that post-trial injections
of PTZ (_20 mg/kg) improved learning of a black-white brightness discrimination.

Animals treated with PTZ reached the

criterion of learning earlier and made fewer errors than did
saline treated animals.

4

Grossman (1969) bilaterally injected PTZ (5-10 ug) directly into the hippocamus of rats before as well as after
traini~g

to perform a brightness discrimination.

PTZ facil-

itated the learning of this discrimination and post-trial injections of PTZ were found to produce a significantly greater effect than pre-trial injections.

It was suggested that

PTZ facilitated learning by activating neural pathways concerned with memory consolidation processes.
Hunt and Bauer (1969) reported that subconvulsive doses
(7.5-15 mg/kg) of PTZ, when injected immediately or 15 min
following training of a black-white brightness discrimination, facilitated learning.

Animals retested 24 h after

training performed significantly better than saline treated
animals.

In a position discrimination task, Hunt and Bauer

(1969) reported that PTZ (10 mg/kg) maximally facilitated
learning when injected 10 min after training.
Bauer (1969) injected subconvulsive doses of PTZ daily
for 20 days and reported this dosage regimen to facilitate
learning of a shuttle box avoidance or a brightness discrimination task when testing occurred 24 h after the last PTZ
injection.

Interestingly, Bovet et al.

(1966) had reported

that whereas strychnine or picrotoxin enhanced shuttle avoidance learning, PTZ (5 or 10 mg/kg) did not. Buckholtz (1974)
also reported that PTZ (20 mg/kg) did not facilitate shuttle
avoidance learning.

Using a wheelturn avoidance procedure,

Krivanek (1971) reported subconvulsive doses of PTZ facilitated learning.

5

For the most part, studies employing subconvulsive doses
of PTZ demonstrate that this drug facilitates learning.

It

has been suggested that PTZ produces this effect by facilitating memory consolidation.

Impairment of Learning
An impairment or loss of memory for events preceding a
trauma is referred to as retrograde amnesia.

Whereas subcon-

vulsive doses of PTZ are reported to facilitate learning,
convulsive doses of this drug produce retrograde amnesia or
impair learning.
Palfai and Chillag (1971) reported that a convulsive
dose (50 mg/kg) of PTZ, when injected up to 20 but not 60
min after training produced retroqrade ar.mesia in mice for
a step-through passive avoidance task.

The degree to which

PTZ produced retrograde amnesia was directly related to the
intensity of the foot shock indicating that the nature of
the original traumatic experience contributed towards the
temporal characteristics of the retrograde amnesia.

Because

electroconvulsive shock had previously been reported to produce retrograde amnesia Palfai and Chillag (1971)

suggested

that a "massive neural explosion" causes retrograde amnesia.
Palfai and Kurtz (1973) reported that this convulsive
dose of PTZ injected 15, 30 or 60 min but not 4 hr before a
single step-through passive avoidance training impaired retention performance 24 h later.

Interestingly, when this

dose of PTZ was injected inunediately after the training trial

6

it did not immediately produce retrograde amnesia, but rather
the amnesia became apparent 4.5 h following the PTZ injection.
These data indicate that a convulsive dose of PTZ can affect
memory for a long (24 h) time after injection.

Palfai and

Kurtz (1973) suggested that PTZ may produce dissociated memory consolidation and that PTZ did not immediately produce
amnesia because the drug state in which memory consolidation
took place was still present when the rats were tested.

How-

ever, when the animals were tested 4.5 h after the PTZ injection a different brain state may have existed that resulted
in impaired retention.
Kurtz and Palfai (1973) tested for a dissociated or
state-dependency hypothesis for the memory impairment produced by PTZ.

Using the step-through passive avoidance task

(Palfai and Kurtz, 1973), results were suggestive for the
state-dependency hypothesis but PTZ produced a general depression of activity that may have confounded this interpretation.

Therefore, Kurtz and Palfai (1973) used a discrimi-

nated escape paradigm to test for dissociative properties
of PTZ.

When reversal training and testing occurred under

similar physiological states, i.e., both following PTZ injection (PTZ-PTZ) or both in the non-drug state (salinesaline), test performance was unimpaired.

However, when PTZ

was injected before reversal training but not before testing (PTZ-Saline) or vice versa (Saline-PTZ) test performance
was impaired.

These data suggest that retrograde amnesia

produced by a convulsive dose of PTZ was related to its dis-

7

sociative or state-dependent effects.

Furthermore, these data

suggest the PTZ seizures may interfere with memory retrieval
rather.than memory consolidation.
To determine if convulsions were necessary for PTZ to
produce state-dependent learning, Palfai and Kurtz (1976)
tested for the ability of a subconvulsive dose (30 mg/kg) of
PTZ to produce this phenomenon.

Unlike the convulsive dose

of PTZ that produced symmetrical dissociation, the subconvulsive dose produced asymmetrical dissociation, that is,
whereas training in the non-drug state did transfer to the
drug state during testing, training in the drug state did
not transfer to testing in the non-drug state.

Electroen-

cephalographic (EEG) changes were still evident at the time
when training and testing took place after injection of the
convulsive dose but not the subconvulsive dose.

Therefore,

the EEG correlates could explain the asymmetrical dissociation produced by the non-convulsive dose of PTZ.
Whereas it was suggested (Weissman, 1968) that only
convulsive doses of PTZ produce retrograde amnesia, van
Buskirk and McGaugh (1974) reported that in Ha/ICR mice subconvulsive as well as convulsive doses of PTZ, injected after
training of a passive avoidance task, impaired retention of
the task.

However, in C57 BL/6J mice convulsive doses of

PTZ did not impair retention.

Not only do these data point

out species differences with respect to the effect of PTZ in
producing retrograde amnesia, these data also indicate that
convulsions are not a prerequisite for PTZ to induce retro-

8

grade amnesia.

The data of Essman (1968) and Vinnitsky and

Abulzade (1971) was cited by van Buskirk and McGaugh (1979)
as supporting the suggestion that seizures are not required
for the retrograde amnesia effect of PTZ.

Essman (1968) re-

ported that a post-trial convulsive dose (60 mq/kg) of PTZ
produce retrograde amnesia even when the convulsions were
blocked by lidocaine pretreatment.

A similar finding was re-

ported by Vinnitsky and Abulzade (1971)
thetic agents.

using other anes-

However, Palfai and Albula (1976a) criti-

cized the data of Essman (1968), pointing out that lidocaine
only partially blocked the seizures.

Using a passive avoid-

ance conditioning paradigm, Palfai and Albula (1976a) reported that convulsions were necessary for the development
of PTZ-induced retrograde amnesia.

These authors reported

that subconvulsive doses (10 or 30 mg/kg) of PTZ did not
produce retrograde amnesia and that animals pretreated with
pentobarbital to block PTZ convulsions did not show retrograde amnesia.
Convulsive doses of PTZ have also been reported to produce retrograde amnesia for classically conditioned fear and
taste aversions.

Palfai and Cornell (1968) reported that

seizures produced by PTZ caused amnesia for classically conditioned fear when PTZ was injected immediately following the
conditioning trial.

Subconvulsant doses of PTZ or convul-

sant doses injected 4 or 24 h (Palfai and Albula, 1976b) after training did not produce amnesia. Retrograde amnesia
produced by PTZ was still evident 1 week after PTZ adminis-
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tration.

Ahlers and Best (1972) reported that convulsions in-

duced by PTZ produced amnesia for a conditioned taste aversion
to a n?vel taste produced by injections of apomorphine.
ner and Palfai (1975) injected PTZ (40 mg/kg)

Mill-

2 min before,

immediately or 3 min after injection of LiCl and reported conditioned aversion to the taste of saccharin.

Kessler and

Gellhorn (1943) had also reported that a convulsive dose of
PTZ disrupted conditioned behavior.
Putney and McCoy (1976) found that a subconvulsive dose
(10 mg/kg) of PTZ enhanced the ability of subthreshold electroconvulsive (ECS) shock to produce retrograde amnesia.
Whereas ECS administration alone given 60 min after passive
avoidance learning did not produce amnesia, injection of PTZ
plus ECS produced amnesia.

Possible Chemical Basis of PTZ-Induced Retrograde Amnesia
Essman (1968) reported that a convulsive dose (60 mg/kg)
of PTZ injected immediately following a single trial to establish a passive avoidance response produced retrograde

a~ne

sia for the task but did not significantly change the brain
ribonucleic acid (RNA) concentration.

Therefore whereas the

amnesia effect of some agents has been attributed to their
ability to decrease brain RNA (for review see Seiden and
Dykstra, 1977), retrograde amnesia produced by PTZ could
not be correlated with a change in brain RNA.
Palfai et al.

(1974) reported a reduction in whole brain

norepinephrine at 5 min but not one or 24 h after injection
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of a convulsive dose (50 mg/kg) of PTZ in mice trained in a
passive avoidance paradigm.

Because the time course of ante-

rograde amnesia reported by Palfai and Kurtz

(1973) was sim-

ilar to the time course of the brain norepinephrine decrease
and recovery it was suggested that normal norepinephrine levels in brain during the early phase of memory storage may be
necessary for retention.

However, convulsions produced by

PTZ have been reported to alter the brain levels of several
other neurotransmitters (see next section:

Neurochemical

Action of PTZ) therefore these substances must also be looked
at with respect to their possible involvement in mediating
the amnestic effect of PTZ before any conclusion can be made
concerning norepinephrine.
Iuvone et al.

(1977) reported that immediate post-train-

ing administration of subconvulsive (50 mg/kg) or convulsive
(60 mg/kg) doses of PTZ resulted in significant retention
deficits on step-through inhibitory avoidance behavior. These
doses also inhibited the incorporation of 3tt-lysine into
brain protein during the first 10 min after training and PTZ
injection.

These data suggest a relationship between inhibi-

tion of protein synthesis and PTZ-induced retrograde amnesia.
Bookin and Pfeifer (1977) injected lysine vasopressin
(_LVP). one hour prior to the acquisition trial and retention
trial in a passive avoidance task and reported that LVP facilitated passive avoidance retention and antagonized amnesia for retention of the task produced by PTZ (50 mg/kg).
Because PTZ has been proposed to exert its amnestic effect
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by interfering with retrieval process (Kurtz and Palfai, 1973)
it was proposed that LVP may exert its anti-PTZ effect by facilita~ing

retrieval processes or blocking the PTZ-induced

interference with retrieval.

PTZ-Induced Amnesia as a Tool to Screen Anti-Petit Mal Drugs
Clincke and Wauquier (1979) reported that a subconvulsive dose (40 mg/kg) of PTZ, injected 30 min before testing,
impaired retention of behavior in a step-down passive avoidance procedure.

Pretreatment, 5 min before PTZ, with the

anti-petit mal drugs ethosuximide, trimethadione or clonazepam antagonized amnesia produced by PTZ.

In contrast drugs

ineffective against petit mal epilepsy including phenobarbital, diphenylhydantoin, haloperidol, amphetamine, valproic
acid or carbamazepine did not antagonize the amnestic effect
of PTZ.

These data suggest that this paradigm might be use-

ful to screen effective anti-petit mal drugs from other antiepileptic and nonspecific drugs.

Conclusion
In a number of different paradigms subconvulsive dose
of PTZ injected before or after training of a learning task
facilitate learning or enhance retention whereas convulsive
doses of this drug impair retention or produce amnesia. These
effects are time dependent for the task.
for these effects of PTZ are unclear.

The exact mechanism

However, it has been

suggested that subconvulsive doses may facilitate learning
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by facilitating memory consolidation whereas convulsive does
impair retention by interfering with the retrieval.

B.Neurochemical Actions of Pentylenetetrazol
Introduction
Pentylenetetrazol (1,5-pentamethylenetetrazole, Metrazol) is an analeptic drug which stimulates all levels of the
neuroaxis.

Pentylenetetrazol (PTZ) has been the most exten-

sively studied analeptic, however its mechanism of action is
poorly understood.

Good reviews of the early literature

(Hildebrandt, 1937; Hahn, 1960) and the chemistry of the
tetrazole derivatives (Benson, 1947) are available.

The pre-

sent review will concern the effect of PTZ on CNS acetylcholine, GABA and monoamine metabolism as well as the effect of
manipulation of brain monoamine levels on PTZ seizure threshold.
Effect of PTZ on Acetylcholine
Acetylcholine Levels
Giarman and Pepeu (1962) sacrificed rats 12 minutes
after a convulsant (75 mg/kg) dose of PTZ and reported a significant (23%) reduction in whole brain acetylcholine.
et al.

(1969)

Beani

sacrificed guinea pigs 30 sec., 3 min. and 6

min. after convulsions produced by PTZ (80 mg/kg) and measured total brain acetylcholine.

The animals sacrificed 6

minutes post PTZ were almost dead at sacrifice with clear
signs of post-seizure neurodepression.

Determination of
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acetylcholine content in brains of guinea pigs sacrificed at
30 seconds or 3 minutes post-PTZ showed that the total amount
of acetylcholine was significantly below control values.

The

reduction in brain acetylcholine produced by PTZ concerned
only bound

~cetylcholine

not free acetylcholine.

In contrast to the reports of Giarman and Pepeu (1962)
and Beani· et al.

(_1969), Nistri and Pepeu (1974) reported that

a subconvulsant (80 mg/kg) or a convulsant (160 mg/kg) dose of
PTZ produced a statistically significant elevation of acetylcholine content in the frog spinal cord after 30 and 15 minutes, respectively.

Bowever, no changes in spinal cord acetyl-

choline levels were noted if the convulsions, interrupted by
periods oj depression, persisted for 90 minutes.

Total frog

brain acetylcholine content was not altered 15 minutes following the administration of the convulsant (160 mg/kg) dose of
PTZ.
The discrepant findings on th_e effect of PTZ on acetylcholine levels may be due to a different effect of PTZ on the
manunalian and amphibian central nervous system.

Acetylcholine Release
Mitchell (_1963) reported that intravenous administration of PTZ

(~50

mg/kg) increased acetylcholine output from

the left and right parietal cortex of sheep.
anesthetized cats Beleslin et al.

In immobilized,

(1965) found that intraven-

ous infusion of PTZ (20-80 mg/kg) produced a dose-dependent
increase in the output of acetylcholine into the cerebral
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ventricles.

Acetylcholine output also increased (2-7 fold)

from the cerebral cortex.

Intraperitoneal injection of PTZ

(150 aRd 300 mg/kg) produced a 2.9 and 7.5 fold increase in
the release of acetylcholine from the cerebral cortex of anesthetized rats (Hemsworth and Neal, 1968).

The increased

release of acetylcholine was nearly maximal during the first
30 minute period of collection after injection and did not
appreciably decrease over a period of 3 hours.

The increase

in release of acetylcholine was associated with increased
electrical activity of the cerebral cortex.
Gardner and Webster (1973) found that intraperitoneal or
intravenous administration of PTZ produced a dose-dependent
increase in Ca ++ dependent acetylcholine efflux from the
cerebral cortex of anesthetized rats which was proportional
to EEG activation and convulsive activity.

A single intra-

peritoneal injection (250 mg/kg) produced a 12-fold increase
in acetylcholine efflux together with convulsive EEG activation.

Trimethadione reduced the PTZ-induced convulsive ac-

tivity, EEG activation and acetylcholine release.

Phenobar-

bital, however, reduced the PTZ-induced EEG and convulsive
activity but left the acetylcholine release relatively unaffected.

Therefore the effect of PTZ on acetylcholine efflux

may not be related to its convulsant effect.
Assuming that increased release of acetylcholine from
brain leads to a reduction in its acetylcholine content the
studies demonstrating PTZ-induced acetylcholine release are
in agreement with the reports of Giarman and Pepeu (1962)
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and Beani et al.

(1969)

demonstrating a PTZ-induced reduction

in brain acetylcholine.

Acetylcholinesterase
Mahon and Brink (1970)

reported that PTZ produced a

concentration-dependent (Ki= 4.7 x 10- 3 M)

competitive inhi-

bition of acetylcholinesterase in crude homogenates of rat
brain.

These authors point out, however, that kinetic con-

stants calculated from their data indicate that the quantity
of PTZ necessary to cause 50 percent inhibition of acetylcholinesterase in vitro is much higher than that amount likely
to be present in the brain after administration of a convulsant dose of the drug.

Furthermore inhibition of acetylcho-

linesterase by PTZ would elevate acetylcholine which is contradictory to existing data (Giarman and Pepeu, 1962; Beani
et al., 1969).
Nistri et al.

(1974) administered PTZ (160 mg/kg)

cutaneously to frogs.

sub-

Twenty minutes after PTZ administration,

when convulsive symptoms were present, the animals were
killed and spinal cord acetylcholinesterase activity was measured.

No significant difference was found between controls

and animals treated with PTZ.

Nistri et al.

(1974) suggested

that the difference between the effect of PTZ on acetylcholinesterase in mammalian brain homogenates and amphibian spinal cord in vivo could reflect a higher resistance of the
amphibian enzyme to PTZ.
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Choline Uptake
When rats were sacrificed immediately after the onset
of the . flexor stage of the convulsion, Simon et al.

(1976)

reported that the intravenous administration of PTZ (75 mg/
kg) produced a 45% increase in sodium-dependent high affinity choline uptake inrat hippocampal synaptosomes.

This in-

crease was not found, however, when cholinergic afferents
to the hippocampus were interrupted by septal lesion prior
to PTZ administration.

Injection of a lower, non-convulsant

(10 mg/kg) dose of PTZ did not result in a change in choline
uptake.
Addition of PTZ (10- 4 M) to hippocampal synaptosomal preparation from saline treated animals did not alter high affinity choline uptake (Simon et al., 1976).
vitro addition had no effect, Simon et al.

Because in
(1976) suggested

that the effect of PTZ is not a direct one synaptosomes but
may be due to an increase in impulse flow.
PTZ increased only the Vmax and not the Km of high affinity choline uptake (Simon et al., 1976).
3
ter the conversion of [ H]-choline to

PTZ is not al-

3
[ H]-acetylcholine

suggesting that the alteration in uptake is not a secondary
effect consequent to a change in choline acetyltransferase
(Simon et al., 1976).
Jenden et al.

(_1976) and Klemm and Kuhar (1979) also re-

ported that convulsant doses of PTZ activated high affinity
choline uptake in hippocampal synaptosomes.

Choline uptake
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rapidly returned toward normal in post-mortem tissue indicating the importance of measuring this process immediately after sacrificing (Klemm and Kuhar, 1979).
In summary, results of experiments investigating the effect of PTZ on acetylcholine function suggest that PTZ activates cholinergic neurons.

Such an activation results in

acetylcholine release, choline uptake and decreased brain
acetylcholine levels.

EFFECT OF PTZ ON GABA
GABA Levels
Kamrin and Kamrin (1961) sacrificed mice during the
tonic extension component of a PTZ-induced seizure and reported no difference in the concentration of brain GABA from
control treated mice.

There was also no difference between

the cerebral concentration of glutamic acid, glycine, taurine
or aspartic acid in PTZ or control treated mice (Kamrin and
Kamrin, 1961).

Tews et al.

(1963) failed to detect any change

in brain GABA concentration of dogs following tonic-clonic
seizures produced by intravenous administration of PTZ (40
mg/kg).

Similarly, Sytinskii and Priyatkina (1966) found no

alteration of GABA concentration in rat brain following convulsions produced by PTZ (100 mg/kg).

Wood and Peesker (1975)

determined mouse brain GABA concentration at the onset of
seizures induced by PTZ and found no difference between PTZ
treated and saline-treated mice.
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Nahorski et al.

(1970) examined rat brain GABA levels at

various times after intraperitoneal administration of a convulsant dose (70 mg/kg) of PTZ and found no change in the
levels of this amino acid until tonic extension when a significant rise was observed.
els was

A similar increase in GABA lev-

also observed when the rats were sacrificed after

the convulsion.

These

autho~s

point out that the increase in

GABA levels may be due to anoxic conditions which existed at
the time of sacrifice.
In contrast to the above reports indicating either no
change or an increase in cerebral GABA during convulsions induced by PTZ, Maynert and Kaji (1962) reported that mice given
PTZ (85 mg/kg) and sacrificed during the first tonic seizure
showed a small but significant decrease in brain GABA concentration.

Wood et al.

(1966) reported a slight but not sta-

tistically significant reduction brain GABA levels when rats
were sacrificed 5 minutes after a convulsant dose (60 mg/kg)
of PTZ.

GABA Release
Johnston and Mitchell (1971) found that PTZ (10

-4

-10

-6

inhibited the resting but not the electrically evoked release
of [ 3 HJ-GABA from rat brain cerebral cortical slices.

By ex-

3
amining the release of [ HJ-GABA from feline cortical slabs,
Reiffenstein (1979) tested the hypothesis that seizure susceptibility of the chronically denervated cortex was due to
interruption of recurrent inhibitory pathways.

PTZ-induced

3
seizures evoked a small increase in [ H]-GABA efflux from

M)
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both the epileptic and the normal cortex.
tion of recurrent inhibitiory

pa~hways

Because

interrup~

would result in de-

creased resting and seizure-evoked release of [ 3 H]-GABA the
above hypothesis was not supported.
GAD/GABA-T
Wood et al.

(1966) reported that PTZ (60 mg/kg) did

not significantly reduce GAD activity in rat brain when rats
were sacrificed 5 minutes after PTZ-induced seizures.

Simi-

larly, Syntinskii and Priyatkina (1966) found no alteration
in GAD activity produced by PTZ either in vivo or in vitro.
Tapia et al.

(1969) also reported a lack of effect of PTZ on

GAD activity.
Sytinskii and Priyatkina (1966) reported that GABA-T activity in rat brain was not changed either by in vivo administration of a convulsant dose of PTZ or by the in vitro addition of PTZ.

However, Wood et al.

(1966) reported that PTZ

(60 mg/kg) produced a significant increase in GABA-T activity.
The increase in GABA-T activity was not correlated, however,
with decreased GABA levels .

Uptake
Johnston and Mitchell (1971) reported that PTZ (10

-4

-

10- 6 M) did not alter [ 3 H]-GABA uptake into rat cerebral cortical slices.

Effectiveness of GABA and GABA-Mimetic Drugs Against PTZ
Hawkins and Sarett (1957) found that orally adrninis-
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tered GABA protected mice from PTZ-induced convulsions.
et al.

(1966)

Wood

reported that GABA but not glycine in a dose of

120 rnrn9les/kg) administered intraperitoneally produced a
slight protection against PTZ-induced convulsions in the rat.
However, several investigators (Purpura et al., 1958 a,b;
Gulati and Stanton, 1960; were unable to demonstrate an anticonvulsant action of GABA following systemic administration.
Kobrin and Seifter (1966) reported that intravenous administration of GABA (25-1000 mg/kg)

to 1 day old chicks in

which the blood-brain barrier was not complete produced a
dose-dependent protection against convulsions induced by PTZ
(35 mg/kg) also administered intravenously.

Several other

w-amino acids including glycine and B-alanine were ineffective.

When GABA was administered to older chicks in which

the blood-brain barrier was developed it was ineffective in
protecting against PTZ-induced convulsions.
et al.

(1969)

Schlesinger

found that intracranial injection of GABA pro-

tected mice against PTZ-induced seizures.
Elevations of brain GABA levels with the GABA-T inhibitors, amino-oxyacetic acid (Roa et al., 1969; Kuriyama et al.,
1966; Wood and Peesker, 1975), hydroxylamine (Roberts et al.,
1960) or valproic acid (Simler et al., 1973) affords protection against PTZ-induced convulsions.
al.

However, Maynert et

(1962) showed that a three-fold elevation of brain GABA

produced by hydrazine did not protect mice against PTZ convulsions.

Similarly, Schecter et al.

(1977) reported that a
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six-fold elevation of brain GABA produced by gamma-acetylenic
GABA did not protect mice against seizures induced by PTZ.
Frey et al.

(1979) examined the role of GABA mechanisms

in PTZ convulsions by investigating the effect of inhibition
of high affinity GABA uptake on PTZ-induced convulsions.

The

ability of inhibitors of high affinity GABA uptake blockers
to increase the PTZ seizure threshold correlated well with
the ability of these drugs to inhibit GABA uptake in vitro.
(-)-Nipecotic acid had the most pronounced effect.

This ef-

fect of the GABA uptake blockers was not correlated with alteration in brain GABA levels or changes in GAD or GABA-T
activities.
The GABA receptor agonist muscimol also elevated the PTZ
convulsant threshold and this was accompanied by decreased
brain GABA concentration and GAD activity (Frey et al., 1979).

Effectiveness of PTZ Against GABA
Presynaptic inhibition is thought to be mediated by
GABA (Barker and Nicoll, 1972; Curtis and Johnston, 1974;
Davidoff, 1972; Davidson and Southwick, 1971) and several investigations have been directed towards examining the effect
of PTZ on GABA mediated presynaptic inhibition.

Boyd et al.

(1966) reported that PTZ blocked GABA mediated presynaptic
inhibition in the cuneate nucleus.
Hazbun (1969) and Hill et al.

Similarly, Banna and

(1974)

GABA-mediated presynaptic inhibition.

found that PTZ reduced
Nicoll and Padjen

2
(1976) found that PTZ in concentration of >l0- M antagonized
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the action of GABA at primary afferents of the isolated frog
spinal cord.
While it appears clear that PTZ blocks GABA-mediated presynaptic inhibition, evidence on the effect of PTZ on GABA mediated post-synaptic inhibition is contradictory.
et al.

(~9661

Krnjevic

reported that PTZ did not block cortical inhibi-

tion mediated by GABA and Hill et al.

(1973a) reported that

slow intravenous infusion of PTZ to cats produced seizure activity without antagonizing the effect of iontophonetic application to the cortex.
Microiontophoretic application of PTZ (lM)

to single fe-

line cortical neurons failed to antagonize the inhibitory effects. of GABA (_Hill

et~

al., 1973b) .

However, the authors cau-

tioned that a sufficient concentration of PTZ to produce GABA
antagonism may not h.ave been achieved in the area of the
neuron when PTZ was applied iontophoretically.
In contrast to th.e above studies showing lack of an effeet of PTZ on GABA-mediated post-synaptic inhibition, MacDonald and Barker (1977) reported that iontophoretically applied pTZ (_0.3Ml competitively inhibited GABA-mediated postsynaptic responses in cultured mammalian spinal cord neurons.
Similarly, Scholfield (1979)
post~·synapt.tc

found that PTZ antagonized the

action of GABA on 9uinea pig olfactory cortical

neurons.
In summary, while PTZ does not alter brain GABA concentration, GAD or GABA-T activity it has been demonstrated that
GABA and some GABA-mimetic drugs antagonize the convulsant
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action of PTZ.

Furthermore, PTZ has been reported to block

both pre- and post-synaptic inhibition mediated by GABA.

EFFECT OF PTZ ON MONOAMINE METABOLISM
Bonnycastle et al.

(1957) reported that a convulsant dose

(75 mg/kg) of PTZ failed to alter rat brain serotonin levels.
However, Bertaccini (1959)

found that rat brain serotonin con-

centration was elevated 20-30% when the animals were sacrificed 15-60 minutes after convulsions.

Garattini et al.

(1960)

also reported that PTZ increased the brain serotonin content
and that this effect was independent of convulsions.
Kato et al.

(1967) looked at the effect of acute and 11

day treatment of PTZ (50 mg/kg)

in rats.

When the animals

were sacrificed 5 minutes after an acute injection there was
an increase in 5-HT levels.

At 2 hours 5-HT levels had re-

turned to normal but were elevated 3-fold at 24 hours.

Sac-

rificing the rats 5 minutes or 24 hours after 11 day PTZ
treatment resulted in marked elevation of 5-HT levels at all
times.
Diaz (1970) injected a subconvulsant (30 mg/kg) dose of
PTZ to rats and reported a 42% increase in brain serotonin
level and a 34% decrease in 5-HIAA level when the animals
were sacrificed 30 minutes after injection.

Administration

of a convulsive (50 mg/kg) dose of PTZ produced an 18% increase in 5-HT level but no change in 5-HIAA level.

PTZ

(.30 mg/kg) produced a significant (48%) decrease in the rate
of 5-HT synthesis, however, 50 mg/kg had no significant
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effect.

The rate of depletion of 5-HT following reserpine was

significantly decreased by PTZ (30 mg/kg) but not the convulsant d9se.

These data show that PTZ alters brain 5-HT metab-

olism and that this effect is not dependent on seizures.
McMillen and Isaac (1974)

reported the effect of PTZ (10-

50 mg/kg) on serotonin and dopamine metabolism in the cat.
Intraperitoneal administration of PTZ (10 mg/kg) produced no
change in the CSF concentration of either 5-HIAA or HVA.
larger, also non-convulsant dose (20 mg/kg)

A

increased the 5-

HIAA concentration by 103% four hours after injection and
5-HIAA levels remained elevated for 24 hours.

HVA levels were

not significantly altered by this dose of PTZ.

When the cats

were administered 30 mg/kg they exhibited a "pseudoconvulsion"
which was characterized by clonus and vocalization.

This

dose of PTZ increased 5-HIAA levels 44% after 4 hours and the
level remained elevated for 24 hours.

HVA levels were found

to be increased 27% after 2 hours but this did not remain elevated for 24 hours as did 5-HIAA levels.

Clonic convulsions

occurred following the administration of a convulsant dose
(50 mg/kg) of PTZ.

This dose produced elevation of 5-HIAA

and HVA which lasted 24 hours.

These data show that non-con-

vulsant doses of PTZ increased metabolic activity in the 5-HT
system for up to 24 hours while not affecting dopamine systems and that convulsions induced by PTZ cause a non-specific
increase in the metabolism of dopamine systems as well.
McMillen and Isaac (1978) later reported that the increase in 5-HIAA levels reported to occur after administration
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of 20 mg/kg PTZ (McMillen and Isaac, 1974) was probably secondary to a reduction in body temperature produced by the drug
since

~aintaining

body temperature prevented the increase in

5-HIAA produced by this dose of PTZ.

Injection of a convul-

sant dose (40 mg/kg) of PTZ increased 5-HIAA levels and this
effect was not prevented by controlling body temperature.
This indicates that convulsant doses of PTZ can increase 5-HT
metabolism but after non-convulsant doses the increase in
5-HT metabolism is secondary to the hypothermic effect of PTZ.
Determination of PTZ concentration in plasma and CSF
showed that PTZ was not present to exert an effect at 24 hours,
therefore the increased levels of 5-HIAA and HVA at this time
was not due to the presence of PTZ (McMillen and Isaac, 1978).
PTZ (20 mg/kg)

did not alter plasma tryptophan levels

and a 40 mg/kg dose decreased total plasma tryptophan.

!This

change is opposite to the change observed in CSF 5-HIAA
(McMillen and Isaac, 1978).

These data suggest that the 24

hour increase in CSF 5-HIAA levels does not result from an increase in plasma tryptophan levels and may be a direct effect
of PTZ on 5-HT neurons.
Pretreatment of cats with trimethadione (200 mg/kg)
blocked the convulsions but not the EEG excitation produced
by PTZ (40 mg/kg).

This dose of PGZ elevated 5-HIAA levels

whether or not the animals were pretreated with trimethadione
suggesting that PTZ can increase 5-HT metabolism without causing convulsions (McMillen and Isaac, 1978).
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The results of Diaz (1970) and McMillen and Isaac (1974,
1978), with respect to the effect of PTZ on 5-HIAA levels,
are opposite.

This discrepancy can best be explained by dif-

ferences in the period of measurement of 5-HT metabolism.

In

addition to its effect on 5-HT and dopamine metabolism, Kato
et al.

(1967) reported that acute administration of PTZ (50

mg/kg) resulted in elevated levels of brain histamine 24 hours
after injection.

Epinephrine levels were decreased at 5 min-

utes and 2 hours after PTZ, not changed after 1 hour and elevated after 24 hours.

Norepinephrine levels were increased

at 5 minutes, 1 hour and 2 hours but had returned to normal
at 29 hours.

Eleven day treatment with PTZ (50 mg/kg) pro-

duced marked elevation in brain histamine but not epinephrine
or norepinephrine (Kato et al., 1967).
In summary, the above studies show that PTZ affects monoamine metabolism at both non-convulsant and convulsant doses.
Furthermore, these effects can last long after the immediate
action of PTZ has stopped.

Effect of Monoamine Manipulation on PTZ Seizure Threshold
Bonnycastle et al.

(1957) reported that elevation of rat

brain 5-HT levels by administration of either iproniazid or
5-HTP failed to protect rats against the convulsant or lethal
effect of PTZ (75 mg/kg).

However, Frey and Kilian (1973)

found that 5-HTP increased the PTZ seizure threshold of both
mice and rats.

Rudzik and Johnson (1970) reported that ad-

ministration of tranylcypromine, 5-HTP or 3,4-dihydroxyphenyl-
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alanine (DOPA) did not alter the PTZ seizure threshold.

How-

ever, when 5-HTP was combined with tranylcypromine a significant elevation in the PTZ convulsive threshold occurred.

In

contrast the combination of tranylcypromine and DOPA did not
increase the threshold for PTZ seizures.
The survival time of mice infused intravenously with PTZ
is shortened by reserpine (Chen et al., 1954; Lessin and
Parkes, 1959; Pfeifer and Galambos, 1967) or tetrabenazine
(Lessin and Parkes, 1959) pretreatment.

Administration of

the MAO inhibitor, iproniazid, prevented the reduction in survival time produced by reserpine (Chen and Bohner, 1961;
Lessin and Parkes, 1959; Pfeiffer and Galambos, 1967) or tetrabenazine (Lessin and Parkes, 1959).

5-HTP lengthened the

survival time of mice pretreated with iproniazid but had no
effect alone.

In contrast, DOPA did not alter the survival

time of mice pretreated with iproniazid (Lessin and Parkes,
1959).

LSD but not 2-bromo-LSD antagonized the effect of

reserpine on PTZ survival time.

LSD did not alter the sur-

vival time of control mice (Lessin and Parkes, 1959) .

These

data suggest a relationship between sensitivity to PTZ and
brain 5-HT levels.

Chen and Bohner (1961) reported that in

addition to 5-HTP, 5-HT, DOPA and dopamine reversed the lowering effect of reserpine on PTZ seizure threshold in iproniazid treated mice.
Jones and Roberts (1968)

found that intracerebroventricu-

lar injection of noradrenaline antagonized reserpine-induced
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facilitation of PTZ seizures but had no effect alone.

Where-

as small amounts of intraventricularly administered dopamine
lowere~

the threshold for PTZ convulsions and were without

effect on the reserpine facilitative effect, higher doses
showed anti-convulsant action and antagonized the facilitative
effect of reserpine.

Schlesinger et al.

(1969) reported that

the combined intracranial injection of norepinephrine plus
5-HT protected mice against PTZ-induced seizures.
Pfeiffer and Galambos (1967) suggested that norepinephrine
has a more important role in the change of susceptibility to
PTZ seizures than 5-HT or dopamine.

These investigators found

that prenylamine decreased the PTZ convulsive threshold without altering 5-HT levels.

Also guanethidine decreased only

brain norepinephrine levels without altering dopamine or 5-HT
and lowered the threshold for PTZ-induced convulsions.
Alexander and Kopeloff (1970) found that pretreatment of
rats with p-chlorophenylalanine (PCPA)

to deplete brain sero-

tonin lowered the threshold for PTZ-induced seizures.

Frey

and Kilian (197 3) pretreated mice with PCPA or cyproheptadine and found no change in the threshold for PTZ-induced
clonic seizures.

However, PCPA lowered the threshold in rats

confirming the data of Alexan'.der and Kopeloff (1970).
Rudzik and Johnson (1970)

reported the PTZ convulsive

threshold in mice was lowered only by drugs which decreased
whole brain 5-HT and was not altered by catecholamine depleting drugs.

Reserpine and P-CPA were found to lower the sei-

zure threshold but U-14,624 and alpha-methyl-para-tyrosine
produced no chage.
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In contrast to these data, Frey and Kilian (1973) reported that alpha-methyl-para-tyrosine, disulfarim, FLA-63
and pr?pranolol but not haloperidol or phentolamine lowered
the threshold for PTZ-induced clonic seizures.

L-dopa ele-

vated this threshold in mice but had no significant effect in
rats.

Because dopamine B-hydroxylase inhibitors were as ef-

fective as alpha-methyl-para-tyrosine and because of the lack
of effectiveness of haloperidol these data suggest a more important role for norepinephrine than dopamine.
The threshold for PTZ-induced tonic extension was depressed by FLA-63, PCPA, cyproheptadine and propranolol but
not

alpha-methyl-p~ra-tyrosine

or disulfarim (Frey and Kilian,

1973).
Corcoran et al.

(1973, 1974) found that selective destruc-

tion of catecholamine but not 5-HT neurons by intraventricular
injection of 6-0HDA to rats pretreated with an MAO inhibitor
increased the duration and intensity of convulsions induced by
PTZ (70 mg/kg).

The severity of seizures in rats with deple-

tion of both norepinephrine and dopamine was not different
from rats with preferential depletion of norepinephrine, suggesting that norepinephrine and not dopamine is important for
the 6-0HDA induced exacerbation of PTZ convulsions.
A number of investigations have looked at the effect of
amphetamines on PTZ seizure threshold.

Kobinger (1958) found

that methamphetamine raised the PTZ seizure threshold when
administered 15 minutes before PTZ.

Methamphetamine also an-

tagonized the decreased PTZ seizure threshold produced by
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reserpine.

Turner and Spencer (1968) however, reported that

d-amphetamine had a pro-convulsant effect on PTZ convulsions
in mice when administered 30-90 minutes before PTZ but had an
anticonvulsant effect when administered 6 hours before PTZ.
BLockade of dopamine but not norepinephrine or 5-HT synthesis
antagonized the pro-convulsant action of d-amphetamine
(Spencer and Turner, 1969) indicating the importance of dopamine for this action.
Rudzik and Johnson (1970) reported that neither d-amphetamine or metharnphetarnine significantly altered the PTZ convulsive threshold but administration of the chloroderivatives
which have a unique effect on 5-HT disposition (Fuller et al.,
1965) produced a significant increase of the PTZ seizure
threshold.

Gerald and Riffee (1973) found that acute admin-

istration of d- or 1-amphetamine increased susceptibility to
PTZ-induced convulsions.
potent as the 1-isomer.

d-Arnphetamine was about twice as
Whereas 1-arnphetamine increased tonic

seizure susceptibility, d-amphetarnine decreased susceptibility to this seizure.

Tolerance developed to these effects

of amphetamine after seven consecutive daily injections
(Gerald and Riffee (1973)).
Finally, Bhattacharya and Sanyal (1978)
prostaglandin E,

reported that

(PGE ) induced inhibition of PTZ-induced
1

seizures in rats was antagonized by drugs which reduce brain
5-HT activity but not by drugs which decrease catecholamine
activity.

Pretreatment with reserpine, P-CPA, methysergide

or 5,6-DHT significantly antagonized PGE

1

induced inhibition
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of convulsions produced by PTZ (60 mg/kg).

Alpha-methyl-para-

tyrosine, diethyldithiocarbamate, phenoxybenzamine, propranolol or . haloperidol pretreatment did not significantly alter
the effect of PGE .
1

These data suggest that this effect of

PGE 1 is not a direct one but is mediated through serotoninergic mechanisms.
In summary, manipulation of CNS monoamines has provided
information regarding the involvement of these neurotransmitters in the convulsant action of PTZ.

The majority of

evidence suggests that reduction of 5-HT or noradrenergic
activity increases the susceptibility to PTZ seizures.

CONCLUSION
Studies to elucidate the action of PTZ on neurotransmitter metabolism have demonstrated that this drug affects
the metabolism of acetylcholine, GABA and monoamines.

A

uniform neurochemical mechanism for the pharmacological actions of PTZ, however, is not apparent.
In addition to its effect on neurotransmitter function,
PTZ has also been reported to have a direct effect on membrane excitability (Gross and Woodbury, 1972; Klee et al.,
1973; David et al., 1974; Suguya and Onozuka, 1978) which
may contribute to its action.
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METHODS

Subjects
A total of 44 male hooded rats of the Long-Evans strain
(Charles River Breeding Laboratories, Wilmington, MA) weighing between 250 and 300 g at the beginning of the investigation were used as subjects.

Animals were housed in single

cages in a large colony room thermostatically maintained at
21 + 1°C.

Room lights were turned off from 8:00 p.m. to

8:00 a.m.

Water was continuously available in the home cages

but food was restricted to 20 g a day made available approximately 4 hours following each operant session.

Apparatus
The behavioral apparatus consisted of conventional Skinner
boxes 24 x 30 cm and 26 cm high enclosed in lightproof, soundattenuated, and fan-ventilated chambers.

Each Skinner box

contained two response levers which were

2~5

extended 2.0 cm into the operant boxes.

One lever was on ei-

cm wide and which

ther side of a food cup which was installed in the center of
the short wall equidistant from each lever.

Scheduling of

behavioral contingencies and recording of data was made by a
combination of eiectromechanical (Lehigh Valley Electronics,
Lehigh Valley, PA) and solid-state (Coulbourn Instruments,
Lehigh Valley, PA) programming equipment.
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PTZ-Saline Discrimination Training
All of the rats were first magazine trained and shaped
to lever press for food reinforcement.

When the rats began

to lever press at a rate of one response per minute they were
shaped to learn a progressively increasing fixed ratio (FR)
schedule of reinforcement until they consistently responded
on an FR 10 schedule (10 lever presses for each 45 mg Noyes
food pellet) .

In the beginning only responses with one of

the levers was reinforced while responding with the other
lever was not reinforced.

When the rats began to respond

with only one lever at a rate of 20 responses per minute the
lever with which responses were reinforced was changed to
the alternate lever.

When the rats began to respond with

this lever at a rate of 20 responses per minute, the lever
with which responses were reinforced was again changed.

Af-

ter 4-5 such alternations without any injection, a PTZ-saline
injection schedule was introduced.

In this phase of train-

ing, daily 15 minute sessions were preceded by injection of
either PTZ (20 mg/kg) or saline (1 ml/kg).

Each session be-

gan with one food pellet in the food cup so as to orient the
rats to the manipulanda. The animals were trained to respond
with one of the levers 15 minutes following a PTZ injection
and the other lever 15 minutes following a saline injection
(Figure 1).

Every tenth response (FR 10) with the appropri-

ate lever was reinforced by delivery of a 45 mg Noyes food
pellet.

Responses with the incorrect lever (i.e., saline
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Figure 1.
Diagrammatic representation of the PTZsa:iLi:ne discrimination . procedure.
On an FR 10 schedule
of food reinforcement, hungry rats were trained to respond with a lever on one side of a food cup 15 min
following a 20 mg/kg PTZ injection and to respond with
the lever on the alternate side 15 min following a
1 ml/kg saline injection.
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lever following PTZ injection or PTZ lever following saline
injection) were recorded but were not reinforced by delivery
of food.
To guard against a possible effect of lever or position
preference the lever with which responses were reinforced
following a PTZ injection was randomly assigned to be the
lever on the right side of the food cup for half of the rats
and the lever on the left side of the food cup for the remaining rats.

For each rat, the position (i.e., right or

left) of the PTZ lever remained constant on each subsequent
session .

To avoid the possibility that olfactory cues asso-

ciated with the correct lever for rats previously tested in
the Skinner boxes could serve as a cue for lever selection
(Weissman, 1976), the sequence of PTZ-saline injections was
varied separately for each group of rats trained successively on the same day.
Initially, the sequence of PTZ-saline injections alternated.

This training continued until five such alternations

were achieved and responding was stabilized with the appropriate lever.

Following this the rats entered the final

phase of training where the PTZ-saline sessions were carried
out seven days a week according to an irregularly alternating sequence of PTZ-saline injections.

In this and all sub-

sequent phases of the experiment, the session length was
fixed at 10 minutes.

The rats were trained to a criterion of

emitting four or less responses with the incorrect lever
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prior to the first reinforcement (10 responses with the correct lever) on nine out of ten consecutive sessions.

Fbr each session data were recorded automatically to include the number of responses emitted with the incorrect lever prior to th_e first reinforcement as well as the total
number of responses emitted with. the correct and incorrect
lever during the entire 10 minute session.

Discrimination Testing_
Wh.en the rats reached the c,riterion described above they
were continuously and repeatedly used for generalization and
anta9onism tes-ting-.
sions

separ~ted

These tests consisted of ten-minute ses-

by at least five practice sessions in which

saline and PTZ wer-e correctly discriminated.

For half of

the rats, the sessions were ·preceded by a practice session
in which saline was injected whereas for the remaining rats
test sessions were preceded by a practice session in which
PTZ was injected.

If the rats•

pe~formance

on these prac-

tice sess·ions seemed to deteriorate with respect to the number of responses on the incorrect lever prior to the first
reinforcement, further training sessions were given before
testing was reinstated.

For generalization and antagonism

testing, doses of each drug were administered in an irregular order.
A.

Generalization Testi·ng

~

Following injection of the

test drug (for pretreatment time see Table 3) each rat was
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placed in its assigned Skinner box and allowed to respond with
the levers until ten nonreinforced responses were completed
with one of the levers.

The lever with which ten responses

were completed first was considered the selected lever and
was subsequently fixed to be reinforced (FR 10) for the remainder of the session.

Responses emitted with the other le-

ver were recorded but not reinforced.

B.

Antagonism Testing - Animals were injected with the

appropriate dose of the test drug or saline.

Following this

pretreatment (for pretreatment time see Table 5), the rats
were injected with pentylenetetrazol (20 mg/kg).

Fifteen

minutes after the pentylenetetrazol injection the animals
were placed in their assigned Skinner boxes and tested for
lever selection as described above.

C.

Antagonism Testing with Diazepam and Chlordiapep-

oxide After Their Chronic Administration - The rats that were
tested acutely with diazepam (2.5 or 10 mg/kg) for antagonism
of the PTZ discriminative stimulus were treated with diazepam
(10 mg/kg) for ten consecutive days.

Similarly, the animals

tested acutely with chlordiazepoxide (2.5 or 10 mg/kg) were
treated with chlordiazepoxide (10 mg/kg) for ten consecutive
days.

Other rats that were tested acutely with solvent were

treated with solvent for ten consecutive days.

Results of

previous studies (Cook and Sepinwall, 1975; Goldberg et al.,
1967; Margules and Stein, 1968; Stein et al., 1975) suggest
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this treatment regimen to be more than sufficient to develop
tolerance to the sedative effects of benzodiazepines.
discri~ination

No

training or test trials were administered dur-

ing this period.

On the eleventh, twelfth and thirteenth

days, animals were injected with the appropriate dose of either diazepam, chlordiazepoxide or solvent and tested for
antagonism of the PTZ discriminative stimulus as described
above for the acute study.

To maintain tolerance for these

days the rats were injected daily with the appropriate drug
four hours after each operant session so that the chronic
dosing schedule was maintained.

D.

Test for Diazepam Antagonism O"f the Discriminative

Stimuli Produced by Cocaine, Yohimb'ine ·a nd R05-3663 in Rats
Trained to Discriminate Between PTZ and Saline - On these
tests rats were treated with diazepam (5 mg/kg) 30 min. before injection of yohimbine
mg/kg).

(2.5 mg/kg) or ROS-3663 (5-20

Thirty min or 1 h after the cocaine injection and

30 min after yohimbine or ROS-3663 injection the rats were
tested for lever selection as described previously.

E.

Test for Diazepam and Halbperidc>l Antagohis:m of

Discriminative Stimulus Produced by Cocaine ih Rats Tra·i ·ned
to Discriminate Between PTZ and Saline - On these tests rats
were injected with diazepam (5 mg/kg) or haloperidol
or 0.69 mg/kg) 30 or

~O

(0.16

min before injection of cocaine

(20 mg/kg), respectively.

Fifteen min after the cocaine in-

jection the rats were tested for lever selection as described
previously.
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Drugs
The drugs used in this study (listed in alphabetical order) were aceperone (Janssen Pharmaceutica N.V., Beerse,
Belgium); amitriptyline hydrochloride (Merck and Co. Inc.,
Rahway, NJ); d-amphetamine sulfate (Smith, Kline and French
Laboratories, Philadelphia, PA); apomorphine hydrochloride
(Eli Lilly and Co., Indianapolis, IN); atropine sulfate (Merck
and Co. Inc. Inc., Rahway, NJ); bemegride (Aldrich Chemical
Co. Inc., Milwaukee, WI); bicuculline methiodide (Pierce Laboratories, Rockford, IL); caffeine citrate (The New York
Quinine and Chemical Works, Inc., New York, NY); carbachol
(Aldrich Chemical Co. Inc., Milwaukee, WI); chlordiazepoxide
hydrochloride (Hoffman LaRoche Inc., Nutley, NJ); chlorpromazine (Smith, Kline and French Laboratories, Philadelphia, PA);
clobazam (Hoechst-Roussel Pharmaceuticals Inc., Somerville,
NJ); clonazepam (Hoffman LaRoche, Inc., Nutley, NJ); clonidine
hydrochloride (Boehringer Ingelheim Ltd., Ridgefield, CT);
cocaine hydrochloride (Merck and Co. Inc., Rahway, NJ); diazepam (Hoffman LaRoche Inc., Nutley, NJ); diphenylhydantoin
(Kand K Laboratories, Plainview, NY); ethanol (U.S. Industrial Chemical Co., New York, NY); ethosuximide (Parke, Davis
and Co., Detroit, MI); etomidate sulfate (Janssen Pharmaceutica
N.V., Beerse, Belgium); £luoxetine (Eli Lilly and Co., Indianapolis, IN); flurazepam dihydrochloride (Hoffman LaRoche Inc.,
Nutley, NJ); gamma-acetylenic GABA (Merrell International Research Center, Strasbourg, France); gamma-hydroxybutyrate
(Aldrich Chemical Co., Milwaukee, WI); gamma-vinyl GABA (Merrell
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International Research Center, Strasbourg, France), haloperidol (McNeil Laboratories Inc., Fort Washington, PA); 5-DLhydroxytryptophan (Aldrich Chemical Co., Milwaukee, WI);
meprobamate (Wallace Laboratories, Cranbury, NJ); 3-mercaptoproprionic acid (Sigma Chemical Co., St. Louis, MO); methylphenidate hydrochloride (Ciba-Geigy Corp., Summit, NJ); methysergide maleate (Sandoz Pharmaceuticals, Hanover, NJ); morphine sulfate (Merck and Co. Inc ., Rahway, NJ); naloxone hydrochloride (Endo Laboratories, Garden City, NJ); nicotine
(Aldrich Che:m ical Co. Inc., Milwaukee, WI) ; oxotremorine
(Aldrich Chemical Co., Milwaukee, WI); pentobarbital (American
Pharmaceutical Co., Bronx, NY); pentylenetetrazol (Sigma Chemical Co., St. Louis, MO); phenobarbital (American Pharmaceutical Co., Bronx, NY); physostigmine sulfate (Merck and Co.
Inc., Rahway, NJ): picrotoxin (Aldrich Chemical Co. Inc.,
Milwaukee, WI); propranolol hydrochloride (Ayerst Laboratories,
Inc., New York, NY); ROS-3663 (Hoffman LaRoche Inc., Nutley,
NJ}; scopolamine hydrobromide (Robbins Research Laboratories,
Richmond, VA}; strychnine sulfate (Mallinckrodt Chemical
Works, St. Louis, MO); trimethadione (Abbott Laboratories,
North Chicago, IL); valproic acid (Abbott Laboratories, North
Chicago, lL); and yohirnbine hydrochloride (Sigma Chemical Co.,
St. Louis, ,MO}.
Dizepam, clobazam, clonazepam and meprobamate were homogenized in 0.9% saline containing 13% propylene glycol and 1%
Tween 80.

Ealoperidol was dissolved in 0.3% tartaric acid.

Trimethadione was dissolved in 0.9% saline containing 40%
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propylene glycol and 10.5% ethyl alcohol.

All other drugs

were dissolved in 0.9% saline.
All drugs were administered intraperitoneally in a volume
of 1 ml/kg except caffeine citrate, clobazam, diazepam, diphenylhydantoin, ethanol, ethosuximide, ganrrna-hydroxybutyrate,
naloxone hydrochloride, R05-3663, trimethadione and valproic
acid and yohimbine hydrochloride which were administered in a
volume of 2-8 ml/kg.

Drug doses were calculated in terms of

the salt.
Statistical Analyses
Lever selection data was expressed as a percentage of
rats selecting the PTZ lever following each drug treatment.
The Fisher Exact Probability Test was used to determine statistical significance of results.

Drug treatments were con-

sidered to significantly generalize to the PTZ discriminative
stimulus if the Fisher Exact Probability Test revealed that
such treatments resulted in a percentage of rats selecting the
PTZ lever that was not significantly (p >0.05) different from
the percentage of rats selecting the PTZ lever after injection of PTZ (20 mg/kg).

Drug pretreatments were considered

to significantly antagonize the PTZ discriminative stimulus
if the Fisher Exact Probability Test revealed that such treatments resulted in a percentage of rats selecting the PTZ
lever that was significantly different (p <0.05)

from the per-

centage of rats selecting the PTZ lever after saline pretreatrnen t.
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Regression analysis was performed to determine whether
generalization to or antagonism of the PTZ discriminative
stimulns by a drug treatment was a dose-related effect.

Drug

treatments were considered to produce a significant doserelated effect if by regression analysis p < 0. 05.

ED 50s and

95% confidence limits were calculated according to Finney
( 19 52) .
To determine whether a drug treatment significantly affected response rate, One Way Analysis of Variance (ANOVA)
was performed to compare mean test session response rate with
mean response rate of the PTZ and saline sessions preceding
the test.

A drug treatment was considered to significantly

affect response rate if One Way ANOVA revealed a statically
significant (p < 0.05) difference among the treatment means.
If One Way ANOV revealed a statistically significant difference among treatment means, a Duncan's Multiple Range Test
(Duncan, 1955) was performed to determine which particular
mean differed from another particular mean.

Mean response

rates were considered to significantly differ from each other by Duncan's vultiple Range Test if p<0.05.
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RESULTS

Acquisition of the PTZ-Saline Discrimination
All of the rats acquired the PTZ-saline discrimination
to the required criterion.

The number of sessions needed to

reach this criterion ranged from 16 to 49, the mean
being 30+ 1.1.

(~S.E.M.)

Acquisition of the PTZ-saline discrimination

is shown in Figure 2.

On the first training session, 43% of

the rats injected with PTZ selected the PTZ lever and 55% of
-

the animals injected with saline selected the PTZ lever.

On

the twentieth training session, 73% of the rats injected with
PTZ selected the PTZ lever and 28% of the rats injected with
saline selected the PTZ lever.

By the thirty-sixth training

session, 95% of the animals injected with PTZ selected the
PTZ lever and 10% of the animals injected with saline selected the PTZ lever.
The number of responses emitted with the incorrect lever
prior to correct lever selection during acquisition of the
PTZ-saline discrimination is shown in Table 1.

On the first

PTZ training session, the rats emitted 31+11.l responses
with the saline lever before selecting the PTZ lever.
the first saline session the rats emitted

34~6.8

On

responses

with the PTZ lever before selection of the saline lever.
the twentieth training session the rats injected with PTZ
emitted 13+4.0 responses with the saline lever prior to

On
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Figure 2.

Acquisition of PTZ-saline discrimination. Values
are the percentage of rats selecting the PTZ
lever or the indicated training session when an
injection of PTZ or saline was given.
Data are
based on 44 rats.
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TABLE 1.

Training
Session
Injection
Numberl

Responses Emitted with the Incorrect Lever Prior to
Lever Selection During Acquisition of the Pentylenetetrazol (20 mg/kg) - Saline Discrimination

Responses with Saline
Lever Following PTZ
(20 mg/kg) Injection
(Mean+ S.E.)2

Responses with PTZ
Lever Following
Saline Injection
(Mean+ S.E.)3

1

31+11.l

34+6.8

4

18+4.7

39+9.l

6

22+5.5

27+4.7

8

15+3.5

21+6.0

10

10+1.9

22+5.5

12

8+2.2

16+5.l

14

7+1.7

14+3.l

16

8+2 . 6

11+3.5

18

7+2.1

11+3.6

20

13+4.0

8+2.3

22

5+1.6

24

6+2.7

8+3.2
·9+2. 6

26

11+3.3

9+2.0

28

4+1.3

7+2.0

30

6+2.3

2+0.5

32

3+1.0

5+1.6

34

4+1.7

5+1.7

36

1+0.6

3+1.2

1 PTZ or saline were administered daily in an irregularly alternating sequence.
2

Responses (Mean+S.E.) emitted with the saline lever prior to
selection of the-PTZ lever (10 responses with PTZ lever) on
days when PTZ (20 mg/kg) was injected.
3 Responses (Mean+S.E . ) emitted with the PTZ lever prior to
selection of the-saline lever (10 responses with saline
lever) on days when saline (1 ml/kg) was injected.
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selection of the PTZ lever and following saline injection the
rats emitted 8+2.3 responses with the PTZ lever before selection of the saline lever.

By the thirty-sixth training ses-

sion the rats injected with PTZ emitted

1~0.6

responses with

the saline lever before PTZ lever selection and following saline injection the rats emitted 3+1.2 responses with the PTZ
lever before saline lever selection.

During acquisition of

the PTZ-saline discrimination there was a significant {R=0.82
and 0.91; p< 0.05) decrease in the number of responses emitted
with the saline lever prior to PTZ lever selection and vice
versa.

During the last ten sessions before generalization

and antagonism testing began these rats emitted only 2.5
(+0.44) responses with the saline lever after PTZ injection
and 3.1
jection.

(~0.43)

responses with the PTZ lever after saline in-

During subsequent testing the rats continued to

reliably discriminate between PTZ and saline (Table 3) .

Effect of Varying Pentylenetetrazol Pretreatment Time on Lever
Selection in Rats Trained to Discriminate Between Pentylenetetrazol and Saline (Table 2) . - One hundred percent of the
rats selected the PTZ lever when the training dose (20 mg/kg)
of PTZ was administered 15 min before testing for lever selection.

Ninety percent of the rats tested for lever selec-

tion 5 or 30 min after PTZ (20 mg/kg) injection selected the
PTZ lever and 80% selected the PTZ lever when tested for
lever selection 60 min following the PTZ injection.

When

tested for lever selection 2 h after PTZ injection 63% of the
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TABLE 2.

Effect of Varying Pentylenetetrazol Treatment Time
on Lever Selection in Rats Trained to Discriminate
Pentylenetetrazol from Saline

Pretreatment Time 1

N2

% Selecting PTZ Lever

5 min

10

90

15 min

10

100

30 min

10

90

60 min

10

80

2 h

8

63

4 h

8

13

24 h

10

0

1

3

Rats were injected i.p. with PTZ (20 mg/kg). Following the
specified pretreatment time the rats were placed in their
assigned Skinner box and allowed to make a lever selection.
The lever with which ten responses were completed first was
considered the selected lever.
2

Nurnber of rats tested.

3Percent of rats selecting PTZ lever.
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rats selected the PTZ lever.

This was not significantly dif-

ferent (Fisher Exact Probability; p > 0.05), however, from 100%
PTZ lever selection when lever selection was tested 15 min
after PTZ (20 mg/kg).

In contrast PTZ lever selection 4 or

24 h after PTZ injection was significantly different (Fisher
Exact Probability, p< 0.05)

from lever selection 15 min after

PTZ injection as only 13% and none of the rats tested selected
the PTZ at these times.

Generalization Testing (Tables 3 and 4)
1.

Anxiogenic CNS Stimulants.
The training dose of PTZ generalized to lower doses

of PTZ in a dose dependent (R=0.98, p < .05) manner.

Whereas,

none of the rats selected the PTZ lever following a 2.5 mg/kg
PTZ injection, 28, 50 and 100% of the rats selected the PTZ
lever following injection of 5, 10 and 20 mg/kg of PTZ (Table
3).

The ED50 was 8 (5.9-10.8) mg/kg.

0.3~0.25,

0.5~0.37,

0.7+0.39 and

The rats emitted

l.1~0.51

responses with the

nonselected lever prior to lever selection following injection of 2.5, 5, 10 and 20 mg/kg of PTZ, respectively (Table 3).
These doses of PTZ did not produce overt convulsions or myoclonus which were observed to occur when PTZ (40 mg/kg) was
administered to naive rats.

Following approximately 6 months

of the PTZ-saline discrimination, however, some of the rats
began to develop myoclonus after PTZ (20 mg/kg) injection.
When PTZ (2.5-20 mg/kg) was administered to these rats the
percentage selecting the PTZ lever was not significantly
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different (Fisher Exact Probability, p > 0.05) from the percentae of rats selecting the PTZ lever following the acute administration of these doses of PTZ.

Response rates during test

sessions when PTZ (2.5-20 mg/kg) was administered were not significantly different (One-Way Analysis of Variance, p > 0. 05)
from the response rates of these rats on the PTZ or saline sessions preceding these tests.
Following injection of 5, 10 and 20 mg/kg of cocaine O,
17 and 86% of the rats selected the PTZ lever (R=0.94, p<0.05).
The ED50 was 13.9 (9.5-20.3) mg/kg.
0.20, l.5+0.81 and

l.7~1.12

These rats emitted 0.3+

responses with the nonselected

lever prior to lever selection.

One rat injected with cocaine

(20 mg/kg) did not make a lever selection.

Response rate

during the cocaine (5 mg/kg) generalization test was significantly greater than (Duncan's Multiple Range Test, p<0.05)
response rate during the preceding PTZ and saline sessions.
After cocaine (10 mg/kg) the rats emitted 1046+77 responses.
This was significantly greater (Duncan's Multiple Range Test,
p<0.05) than the 806+53 responses emitted during the preceding PTZ session but not significantly different (Duncan's
Multiple Range Test, p>0.05) from the
emitted the preceding saline session.

1064~66

responses

Following the highest

dose of cocaine (20 mg/kg) response rate was not significantly
different (Fd.f. 2,15=3.04, p>0.05) from response rate during
the preceding PTZ or saline session.
None of four rats injected with yohirnbine (0.16 mg/kg)
selected the PTZ lever.

One out of five rats selected the
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PTZ lever after 0.64 mg/kg yohimbine and one out of four rats
selected the PTZ lever after 10 mg/kg yohimbine.

However, 50%

of twel,ve rats selected the PTZ lever after injection of 2.5
mg/kg yohimbine.

This was significantly different (Fisher Ex-

act Probability, p<0.05) however from 100% PTZ lever selection
after 20 mg/kg PTZ.

During the yohimbine (0.16-10 mg/kg) gen-

eralization tests the rats emitted
3~3.0

3~1.9,

3~1.6,

l.7+0.91 and

responses with the nonselected lever prior to lever se-

lection.

Response rate during the 0.16 and 0.64 mg/kg yo-

hirnbine sessions were not significantly different (F d.f.
2,6=0.44, p>0.05, F d.f. 2,12=1.13, p>0.05) from response rate
during the PTZ or saline sessions preceding these tests.

Re-

sponse rate during the 2.5 mg/kg generalization test was significantly lower (Duncan's Multiple Range Test, p <0.05) than
response rate during the preceding saline session but not signifidantly different (Duncan's Multiple Range Test, p>0.05)
from response rate during the preceding PTZ session.

During

the 10 mg/kg yohimbine session response rate was significantly
lower (Duncan's Multiple Range Test, p<0.05) than response
rate during the pieceding PTZ and saline sessions.
None of six rats injected with strychnine (1.25 mg/kg)
selected the PTZ lever, however, three out of five rats injected with 2.5 mg/kg strychnine selected the PTZ lever.

One

rat did not make a lever selection after injection of the
highest dose of strychnine.

Whereas PTZ lever selection after

the lowest dose of PTZ was significantly different (Fisher
Exact Probability,

p~0.05)

from lever selection after 20 mg/kg

51

PTZ, PTZ lever selection after the highest dose of strychnine
was not significantly different (Fisher Exact Probability ,
p~0.05)

PTZ.

from PTZ lever selection after the training dose of

The rats injected with these doses of strychnine emit-

ted zero and

0.2~0.20

responses with the nonselected lever

prior to lever selection.

Response rates during the strych-

nine (1.25 and 2.5 mg/kg) generalization tests were not significantly different (F>d.f. 2,15=3.45, p>0.05; F d.f. 2,12=
2.76, p 0.05)

from response rates during the PTZ or saline

sessions preceding the tests.
R05-3663 (0.64-5 mg/kg) dose-dependently (R=0.99, p<0.05)
generalized to the discriminative stimulus produced by PTZ.
The ED50 was 2.3 (1.8-2.8) mg/kg.

Whereas none of the rats

selected the PTZ lever following injection of 0.64 mg/kg
R05-3663, 67 and 100% of the rats selected the PTZ lever following injection of R05-3663 at doses of 2.5 and 5 mg/kg, respectively.

During these tests

l.3~0.94,

0.5~0.34

and

l.2+0.80 responses were emitted with the nonselected lever
prior to lever selection.

Response rates during the R05-3663

(0.64-5 mg/kg) generalization tests were not significantly
different (F d.f. 2,6=0.52, p>0.05; F d.f. 2,15=3.ll, P>0.05;
F d.f. 2,15=1.58, p>0.05) from response rates during the PTZ
or saline sessions preceding the tests.
2.

Non-Anxiogenic Stimulants
One out of six rats injected with a-amphetamine

(0.64 lmg/kg) selected the PTZ lever. This was significantly
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different (Fisher Exact Probability, p<0.05)

from 100% PTZ

lever selection after injection of PTZ (20 mg/kg).
emitted

0.8~0.54

These rats

responses with the nonselected lever prior

to lever selection.

Response rate after this dose of d-ampet-

amine was not significantly different (F d.f. 2,15=1.16,
p>0.05) from response rate during the PTZ or saline session
preceding the test.

Three rats injected with d-amphetarnine

(2.5 mg/kg) did not make a lever selection.
None of the rats injected with methylphenidate (2.5-10
mg/kg)

selected the PTZ lever.

the saline lever.
rats emitted

All of these rats selected

Prior to saline lever selection these

0.5~0.34

and zero responses with the PTZ lever.

Response rate after methylphenidate (2.5 or 10 mg/kg) was
not significantly different (F d.f. 2,15=2.31, p>0.05;
F d.f. 2,9=1.99, p>0.05) from response rate during the preceding PTZ or saline session.
None of the rats injected with caffeine (5 and 20 mg/kg)
selected the PTZ lever, whereas 20% of the rats injected
with 80 mg/kg of caffeine selected the PTZ lever.

PTZ lever

selection following caffeine was significantly different
(Fisher Exact Probability, p<0.05) from 100% PTZ lever selection after PTZ (20 mg/kg). After caffeine injection the rats
emitted zero,

0.8~0.48

and

0.2~0.20

responses with the non-

selected lever before lever selection.

During the caffeine

(5 or 20 mg/kg) generalization tests response rates were
not significantly different (F d.f. 2,9=1.30, p>0.05;
F d.f. 2,9=3.44, p>0.05) from response rates during the pre-
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ceding PTZ saline
rats emitted

ses~ions.

228~73

After caffeine (80 mg/kg) the

responses.

This was significantly less

(Duncap's Multiple Range Test, p<0.05) than the 796+121 responses emitted during the preceding saline session but not
significantly different (Duncan's Multiple Range Test, p>0.05)
from the 540+133 responses emitted during the preceding PTZ
session.
3.

Convulsants
Bemegride (1.25-5 mg/kg) dose dependently (R=l.00,

p<0.05) generalized to the PTZ discriminative stimulus.
Whereas none of the rats selected the PTZ lever after a bemegride injection, 50 and 100% selected the PTZ lever after injection of 2.5 and 5 mg/kg bemegride, respectively.
was 2.5 (2.1-2.9) mg/kg.

The EDSO

Whereas zero responses were emitted

with the nonselected lever before lever selection during the
generalization test with bemegride (1.25 and 2.5 mg/kg),
0.6~0.33

responses were emitted with the saline lever prior

to PTZ lever selection during the 5 mg/kg bemegride generalization test.

Response rates during the bemegride (1.25-5

mg/kg) generalization test sessions were not significantly
different (F d.f. 2,6=0.41, p>0.05; F d.f. 2,18=2.87, p>0.05;
F d.f. 2,15=2.92, p>0.05) from rates of responding during the
PTZ or saline sessions preceding these tests.
Fifteen and sixty percent of the rats tested selected
the PTZ lever following injection of 0.32 and 1.25 mg/kg
picrotoxin, respectively.

This was significantly different
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(Fisher Exact Probability, p<0.05) however, from 100 percent
PTZ lever selection following PTZ (20 mg/kg) injection.
ing

th~

Dur-

picrotoxin generalization tests the rats emitted

l.1+0.77 and l.0=0.63 responses with the nonselected lever
prior to lever selection.

Response rate following picrotoxin

(0.32 or 1.25 mg/kg) was not significantly different (F d.f.
2,18=0.83, p>0.05; F d.f. 2,27=1.60, p > 0.05)

from the rate of

responding during the PTZ or saline session preceding the picrotoxin test.

Three rats injected with 2.5 mg/kg picrotoxin

did not make a lever selection.

Higher doses of picrotoxin

produced convulsions in naive rats and therefore were not
tested.
Following injection of 3-mercaptoproprionic acid (5 mg/kg),
40% of the rats selected the PTZ lever.

This was significant-

ly different (Fisher Exact Probability, p<0.05) however from
100% PTZ lever selection after injection of PTZ (20 mg/kg).
These rats emitted 1+1.0 responses with the nonselected lever
prior to lever selection.

During the 3-mercaptopropionic acid

(5 mg/kg) test session the rats emitted 898=94 responses.
This was significantly greater (Duncan's Multiple Range Test,
p<0.05) than the 608+50 responses emitted during the preceding PTZ session but not significantly different (Duncan's
Multiple Range Test, p>0.05) from the 958+84 responses emitted
during the saline session preceding the test session.

Four

rats injected with a 40 mg/kg dose of 3-mercaptopropionic
acid died following convulsions produced by the drug.
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Bicuculline methiodide (1.25-2.5 mg/kg)

failed to produce

PTZ lever selection when administered to the rats trained to
discrim~nate

between PTZ and saline.

All of the rats selected

the saline lever when tested for lever selection after these
doses of bicuculline.

Before saline lever selection these

rats emitted zero and 0.5+0.50 responses with the PTZ lever.
Response rates during the bicuculline (1.25 mg/kg and 2.5
mg/kg) generalization test sessions were significantly different (Duncan's Multiple Range Test, p<0.05)

from response rates

during the PTZ sessions preceding the tests but not significantly different (Duncan's Multiple Range Test, p>0.05)

from

rate of responding during the preceding saline sessions.
None of six rats injected with gamma-hydroxybutyrate
(GHB) at a dose of 160 mg/kg selected the PTZ lever whereas
17% of the rats selected the PTZ lever following a 320 mg/kg
GHB injection.

The percent PTZ lever selection produced by

GHB was significantly different (Fisher Exact Probability,
p<0.05) from 100% PTZ lever selection after PTZ (20 mg/kg).
Higher doses of GHB are hypnotic and therefore were not tested.
The rats treated with GHB 160 and 320 mg/kg, respectively,
emitted 0.2+0.17 and 0.3+0.21 responses with the incorrect
lever prior to lever selection.

Response rate during the

GHB (160 mg/kg) generalization test was not significantly
different (F d.f. 2,15=0.90, p>0.05) from response rate during the preceding PTZ or saline session, however, during the
GHB (320 mg/kg) test response rate was significantly different (Duncan's Multiple Range Test, p

0~05)

from response
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rate during the preceding PTZ and saline session.
Eleven and twenty-five percent of the rats injected with
nicoti~e,

lever.

0.64 a nd 1.25 mg/kg, respectively, selected the PTZ

This was significantly different (Fisher Exact Prob-

ability, p< 0.05) from 100% PTZ lever selection after PTZ
(20 mg/kg).

One rat injected with nicotine (1.25 mg/kg) did

not make a lever selection.
emitted l.3+0.90 and

The rats making a lever selection

l.6~0.90

responses with the nonselected

lever prior to lever selection.

Response rates during the

nicotine (0.69 or 1.25 mg/kg) test sessions were not significantly different (F.d. f. 2,24=0.92, p>0.05; F. d.f. 2,21=2.33,
p>0.05)

from response rates during the PTZ or saline sessions

preceding the tests.

4.

Cholinergic Drugs
None of the rats injected with carbachol (0.32-0.64

mg/kg) selected the PTZ lever.
saline lever.

All of the rats selected the

Prior to lever selection 0.2+0.17 and zero

responses were emitted with the nonselected lever.

Three

rats injected with 0.64 mg/kg carbachol did not make a lever
selection.

The rats emitted 803+203 responses during the

carbachol (0.32mg/kg) generalization test.

This was signif-

icantly less (Duncan's Multiple Range Test, p<0.05) than the
1317+52 responses emitted during the preceding saline session but not significantly different (Duncan's Multiple
Range Test, p>0.05) from the

1117~36

ing the preceding PTZ session.

responses emitted dur-
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Thirty-six percent of eight rats injected with physostigmine (0.64 mg/kg) selected the PTZ lever when this drug
was administered 30 minutes prior to testing.

This was sig-

nificantly different (Fisher Exact Probability, p<0.05) from
100% PTZ lever selection following injection of PTZ (20 mg/kg).
Six rats did not make a lever selection.

Four rats injected

with physostigmine (1.25 mg/kg) and tested 30 minutes after
injection did not make a lever selection.

However when tested

75 minutes after injection, three rats selected the saline
lever and one rat did not make a lever selection.

Zero re-

sponses were made with the nonselected lever prior to lever
selection in all generalization tests with physostigmine.

Re-

sponse rates during the physostigmine (0.64-1.25 mg/kg) generalization tests were significantly different (Duncan's
Multiple Range Test, p<0.05) from response rate during the
PTZ and saline sessions preceding the tests.
The rats injected with oxotremorine (0.32 mg/kg) selected
the saline lever and these rats did not emit any responses
with the PTZ lever before saline lever selection.

Three oth-

er rats did not make a lever selection after 0.32 mg/kg oxotremorine.

Response rate after oxotremorine was not signif-

icantly different (F d.f. 2,6=2.65, p>0.05)

from response

rate during the preceding PTZ or saline session.
Thirty-eight percent of eight rats injected with scopolamine (0.64 mg/kg) selected the PTZ lever. This was significantly different from 100% PTZ lever selection after PTZ
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(20 mg/kg)

(Fisher Exact Probability Test, p<0.05).

rats emitted

0.8~0.75

responses with the nonselected lever

prior t 'o lever selection·.
lection.

These

One rat did not make a lever se-

Response rate during the scopolamine (0.64 mg/kg)

generalization test was significantly less (Duncan's Multiple
Range Test,<p 0.05) than response rate during the PTZ and saline sessions preceding the scopolamine test.
5.

Drugs Affecting Monoaminergic Activity
Thirteen and fifty percent of eight rats selected

the PTZ lever following administration of 0.16 and 0.64 mg/kg
apomorphine, respectively.

The percent PTZ lever sel8ction

after these doses of apomorphine was significantly different
(Fisher Exact Probability Test, p<0.05) from 100% PTZ lever
selection after PTZ (20 mg/kg) .

After apomorphine (1.25

mg/kg) one of two rats selected the PTZ lever and four rats
did not make a lever selection.

Zero,

0.4~0.38

and 0.3 re-

sponses were emitted with the nonselected lever prior to lever selection following these doses of apomorphine.

Response

rate after apomorphine (0.16 mg/kg) was not significantly
different (F d.f. 2,21=1.85, p>0.05) from response rate during the preceding PTZ or saline sessions.

After injection

of 0.64 mg/kg apomorphine, however, response rate was significantly less JDunc·a n'sMultiple Range Test ·, p<0.05) than response rate during the preceding saline session but not significantly different from response rate during the preceding
PTZ session (Duncan's Multiple Range Test, p>0.05).
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Thirty-three percent of six rats injected with propranolol (20 mg/kg) selected the PTZ lever.

This was significant-

ly different from 100% PTZ lever selection after PTZ (20
mg/kg)

(X

2

d.F.1=7.87, P ,<0.05).

These rats emitted l.0+0.82

responses with the nonselected lever prior to lever selection.
Response rate during the propranolol test session was significantly less (Duncan's Multiple Range Test, p<0.05) than response rate during the PTZ and saline session preceding this
test.
All of the rats injected with aceperone (0.64 or 2.25
mg/kg) selected the saline lever and these rats did not emit
any responses with the PTZ lever before saline lever selection.

These rats were removed from the Skinner boxes after

lever selection and therefore response rate is not given.
Twenty-five percent of eight rats selected the PTZ lever after a 100 mg/kg injection of DL-5-hydroxytryptophan
(5-HTP).

This was significantly different (Fisher Exact Pro-

bability, p<0.05) however, from 100% PTZ lever selection after PTZ (20 mg/kg).

These rats emitted 0.3+0.25 responses

with the nonselected lever before making a lever selection.
Two rats did not make a lever selection after this dose of
5-HTP.

Response rate after 5-HTP was significantly less

(Duncan's Multiple Range Test, P<0.05) than rates of responding during the previous PTZ and saline sessions.
After fluoxetine (5 mg/kg), 33 percent of six rats selected the PTZ lever and these rats did not emit any responses with the nonselected lever prior to lever selection.
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Following injection of a higher (10 mg/kg) dose of fluoxetine,
two rats selected the saline lever and two rats did not make
a lever selection .

The rats emitted

566~97

responses during

the fluoxetine (5 mg/kg) generalization test.

This was sig-

nificantly less (Duncan's Multiple Range Test, p<0.05) than
the

1120~82

responses emitted by these rats during the previ-

ous saline session but not significantly different (Duncan's
Multiple Range Test, p> 0.05)

from the

822~76

responses

emitted during the PTZ session preceding the test.

Response

rate after 10 mg/kg fluoxetine was lower than the preceding
PTZ and saline sessions but the small number of rats prohibited statistical analysis.
6.

Opiate Agonist and Antagonists
None of the four rats injected with morphine (2.5

mg/kg) selected the PTZ lever and these rats did not emit
any responses with the PTZ lever prior to saline lever selection.

Response rate after morphine was not significantly

different (F d.f.2,6=1.71, p>0.05) from rates of responding
during the PTZ and saline sessions preceding the morphine
test.
Thirty-three percent of six rats injected with naloxone
(80 mg/kg) selected the PTZ lever and this was significantly
different (Fisher Exact Probability, p<0.05) from 100% PTZ
lever selection after PTZ (20 mg/kg), however.

These rats

did not emit any responses with the incorrect lever prior to
lever selection.

One rat did not make a lever selection after
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TABLE 3 .

Generalization tests with rats trained to discriminate between
pentylenetetrazol (20 mg/kg) and saline.l

Pretreatment
Time
N2
(Minutes)

4
Mean Responses
(+S.E.)with NonSelected Lever
Before Lever
% Selecting
Selection
PTZ Lever3

Test Drug

Dose
(mg/kg)

ACEPERONE

0.64
2.5

30

5
5

0
0

d-AMPHETAMINE SULFATE

0.64
2.5

15

6
6

17
No Selection

0.8+0.54

APOMORPHINE
HYDROCHLORIDE

0.16
0.64
1. 25

15

8
8
2
4

13
50
50
No Selection

0
0.4+0.38
0.3

BEMEGRIDE

1. 25
2.5
5

15

3
6
7

0
50
100

0
0
0.6+0.33

BICUCULLINE
METHIODIDE

1. 25
2.5

10

6
6

0
0

0
0.5+0.50

5
20
80

30

4

0
0
20

0
0.8+0.48
0.2+0.20

0.32
0.64

15

6
1
3

0
0
No Selection

0.2+0.17
0

COCAINE HYDROCHLORIDE

5
10
20

15

6
6
7
1

0
17
86
No Selection

0.3+0.20
1.5+0 .81
l.7+1.12

FLUOXETINE

5
10

15

6
2
2

33
0
No Selection

CAFFEINE CITRATE

CARBACHOL

4

5

0
0

0
1.5

Table 3 continued

Test Drug

GAMMA-HYDROXYBUTYRATE
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Dose
(mg/kg)

Pretreatment
Time
(Minutes)
N2

Mean Responses4
(_±.S.E.)with NonSelected Lever
% Selecting Before Lever
Selection
PTZ Lever

160
320

7

6
6

0
17

10
40

30

5
4

40
lethal

1.0+1.0

.METHYLPHENIDATE

2.5
10

15

6
4

0
0

0.5+0.34
-0

MORPHINE SULFATE

2.5

20

4

0

0

15

6
1
3

33
No se·lection
100

0

3-MERCAPTOPROPIONIC
ACID

NALOXONE
HYDROCHLORIDE

80
160

0.2+0.17
0.3+0.21

a

1.3+0.90
l.6+0.90

NICOTINE

0.64
1.25

15

9
8
1

11
25
No Selection

OXOTREMORINE

0. 32

15

3
3

0
No Selection

PENTYLENETETRAZOL

2.5
5
10
20

15

4
14
14
14

PHYSOSTIGMINE SULFATE 0.64

30

75

36
No Selection
No Selection
0
No Selection

0

1.25
1.25

8
6
4
3
1
7
10
3

14
60
No Selection

1.1+0. 77
1. o+o .63

PICROTOXIN

0.32
1.25
2.5

15

0
28
50
100

0

0.3+0.25
0.5+0.37
0.7+0.39
l.1+0.51

0

Table 3 continued
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4

Test Dr\lg

Dose
(mg/kg)

PROPRANOLOL

Mean Responses
Pretreatment
(±_S . E. ) with NonTime
% Selecting Selected Lever
2
(Minutes)
N PTZ Lever
Before Lever
Selection

20

30

R04-4602 + DL-5HYDROXYTRYPTOPHAN

25
100

60
30

R05-3663

0.64
2.5
5

30

4
6
6

0
67
100

1. 3+0.94
0.5+0.34
1. 2+0 .80

15

14

0

0.4+0.25

0.64

30

8
1

38
No Selection

0.8+0.75

STRYCHNINE SULFATE

1. 25
2.5

15

6
5
1

0
60
No Selection

0
0.2+0.20

YOHIMBINE
HYDROCHLORIDE

0.16
0.64
2.5
10

30

4
5
12
4

0
20
50
25

3+1.9
3+1.6
1. 7+0.91
3+3.0

SALINE
SCOPOLAMINE HYDROBROMIDE

6

33

i . o+o .02

8
2

25
No Selection

0.3+0.25

1

Following pretreatment with the test drug the rats were placed in their
assigned Skinner boxes and allowed to make a lever selection. The lever
with which ten responses were completed first was considered the selected
lever.
2

3

Number of rats tested.

% of rats selecting the pentylenetetrazol lever.
"No Selection" indicates
that 10 responses were not completed with either lever in the 10 min
session due to behavioral toxicity of the drug.
4
Responses (Mean+S.E.) emitted with nonselected lever before lever selection. Where N <3 mean is given.

TABLE 4.

Generalization Tests: Effect of test drugs on response rate in rats trained to discriminate
between pentylenetetrazol (20 mg/kg) and saline.

Responses/10 Min; Mean+S.E.
Test Drug

d-AMPHETAMINE
SULFATE
APOMORPHINE
HYDROCHLORIDE

BEMEGRIDE

BICUCULLINE
METHIODIDE
CAFFEINE CITRATE

CARBACHOL

COCAINE
HYDROCHLORIDE

Dose
(mg/kg)
0.64
2.5
0.16
0.64
1.25

Pretreatment
Time
(Minutes)
15

15

1.25
2.5
5

15

1. 25
2.5

10

5
20
80

30

0.32
0.64

15

5
10
20

15

N2

918+80

898+92
0

118+5
0

98+4
0

1033+95
1164+59
1085
1085+86

900+114
739+148
830
0

112+10
86+17
780

74+11
62+12
75
0

6
3

760+66

8
8
2
4

789+45
850+64
1045
863+96

.

-

4

% PTZ

Saline

-

% + S.E.

Test
Drug

1

PTZ

3

-

-

% Saline

3
6
7

437+104
753+49
726+55

523+43
967+97
965+91

540+57
955+55
834+60

136+26
129+9
116+7

80+37
102+8
91+9

6
6

658+84
623+72

1087+35
1003+48

1038+59
977+61

171+22
168+22

96+4
97+3

4
4
5

428+98
508+65
540+133

198+40
158+23
48+14

122+10
98+12
28+7

-

-

-

-

-

640+247
805+68
796+121

-

6
1
3

1117+36
670
977+19

1317+52
690
1193+28

6
6
7
1

923+61
806+53
843+38
890

1209+35
1064+66
991+74
950

-

-

-

-

743+140
785+124
228+73

-

803+203
710
0
1075+47
1046+77
767+77
0

-

-

-

72+17
106
0
121+10
130+6
93+12
0

-

-

59+14
103
0
88+4
99+6
82+13
0

(J'I
~

TABLE 4 continued

Test Drug
FLUOXETINE

GAMMAHYDROXYBUTYRATE
3-MERCAPTOPROPIONIC ACID
METHYLPHENIDATE

IDRPHINE
SULFATE
NALOXONE
HYDROCHLORIDE

Dose
(mg/kg)

Pretreatment
Time
(Minutes)

2
N

Responses/10 Min; Mean.:!:_S.E.
Test
PTZ
Saline
Drug

3

-%
% PTZ

+ S.E.

4

% Saline

5
10

15

5
2
2

822+76
970
795

1120+82
1110
1170

566+97
300
0

73+12
31
0

51+10
28
,0

160
320

7

6
5

1050+81
842+44

1163+65
1136+60

1053+55
508+127

93+7
58+14

89+3
44+10

10

30

5

608+50

958+84

898+94

148+13

-

96+10

2.5
10

15

6
4

938+78
928+34

1070+48
1173+"51

1133+66
1005+14

123+6
107+12

106+3
85+10

2.5

20

3

927+52

933+37

837+32

90+2

90+7

80

15

6
1
1
3

897+87
590
780
1056+119

1093+91
670
1120
1183+127

452+152
0
510
0

61+27
0
65
0

44+14
0
46
0

160

-

-

-

-

-

-

-

-

NICOTINE

0.64
1.25

15

9
8
1

820+58
836+75
700

971+106
1040+95
860

954+88
805+80
0

OXOTREIDRINE

0.32

15

3
3

1030+140
873+55

1293+32
1060+72

1223+18
0

-

126+8
96+3
0
124+18
0

-

-

112+10
79+4
0
95+1
0

CTI
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TABLE 4 continued

Response/10 Min; Mean±_S.E.

Test Drug

PENTYLENETETRAWL

PHYSOSTIGMINE
SULFATE

PICROTOXIN

PROPRANOLOL
R04-4602+DL-5HYDROXYTRYPTOPHAN

Dose
(mg/kg)

Pretreatment
Time
(Minutes)

2.5
5
10
20

15

0.64

30

1.25
1.25

75

0.32
1.25

15

20

30

25
100

60
30

0.64
2.5
5

30

N2

PTZ

3

% + S.E.

4

-

Saline

Test
Drug

% PTZ

% Saline

4
14
14
14

918+92
691+63
720+39
725+43

1068+122
856+67
859+51
847+56

1105+106
834+78
825+47
718+45

121+7
106+12
112+7
100+4

8
1
4
3
1

815+96

956+98

1060+15
820

1277+55
1030

446+153
0
0
170+95
0

56+20
0
0
15+7
-0

36+14
0
0
14+8
0

121+11
106+11

102+5
91+11

-

-

-

-

104+2
100+4
98+4
88+7

-

10

759+78
810+59

916+108
992+97

924+118
829+77

6

858+70

953+70

465+86

54+10

50+9

8
2

980+89
680

1103+12
750

267+39
-0

27+4
-0

24+4
-0

4
6
6

520+147
433+60
396+64

653+62
673+83
587+140

142+35
163+18
92+9

101+9
104+9
69+10

14

805+49

981+74

126+8

104+2

7

-

-

-

-

-

R05-3663

SALINE

15

-

-

-

-

667+111
702+103
370+67

-

1004+70

-

-

-

-

(J\
(J\

TABLE 4 continued

Response/10 Min; Mean+S.E.
Test Drug

Dose
(mg/kg)

Pretreatment
Time
(Minutes)

N2

PTZ

Saline

3

Test
Drug

% + S.E.

% PTZ

4

% Saline

SCOPOLAMINE
HYDRO BROMIDE

0.64

30

8
1

853+54
670

1173+47
910

479+125
-0

55+13
0

33+10
-0

STRYCHNINE SULFATE

1.25
2.5

15

6
5
1

818+69
908+"44
880

1037+63
1024+51
1110

1032+69
620+206
0

129+13
68+21
0

100+5
62+20
0

YOHIMBINE
HYDROCHLORIDE

0.16
0.64
2.5
10

30

4
5
8
3

490+110
426+102
569+40
556+145

567+72
438+84
643+75
117+92

129+30
114+15
112+9
18+11

94+2
72+9
67+6
18+15

600+65
600+88
828+41
853+213

1

Test drugs were administered intraperitoneally. Following pretreatment with the test drugs the rats
were placed in their assigned Skinner box and allowed to respond with the levers for 10 min.
2Number of rats tested.
3Total responses (Mean.:t_S.E.) emitted during the 10 min session following test drug treatment and
during the preceding pentylenetetrazol (20 mg/kg) and saline session.
4values were obtained by dividing the total number of lever presses emitted following test drug by
the total number of responses during the preceding pentylenetetrazol (20 mg/kg) and saline session.

CTI
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this dose of naloxone.

After naloxone (160 mg/kg), one rat

selected the PTZ lever and three rats did not make a lever
selection.

Response rate after naloxone (80 mg/kg) was sig-

nificantly less (Duncan's Multiple Range Test, p<0.05) than
the response rate during the PTZ and saline sessions preceding the naloxone test.

Antagonism Testing (Tables 5 and 6)
1.

Effect of Benzodiazepines, Meprobamate and Barbitur-

ates
Pretreatment of rats trained to discriminate PTZ
(20 mg/kg) from saline with either saline or 86% saline, 1%
Tween and 13% propylene glycol failed to antagonize the discriminative stimulus produced by PTZ.

All of the rats pre-

treated with the solvents selected the PTZ lever.
treated with saline emitted

0.5~0.37

Rats pre-

responses with the sa-

line lever prior to PTZ lever selection whereas rats pretreated with 86% saline 1% Tween 80 and 13% ·propylene glycol
emitted 0.3+0.29 responses with the saline lever before PTZ
lever selection.

Rate of responding during the saline antag-

onism test was not significantly different (F d.f. 2,39=0.38,
p>0.05) from response rate during the PTZ or saline session
preceding the test.

Response rate after 86% saline, 1% Tween

80 and 13% propylene glycol treatment however, was significantly less (Duncan's Multiple Range Test, p<0.05) than response rate during the preceding saline session but not significantly different (Duncan's Multiple Range Test, p>0.05)
from response rate during the preceding PTZ session.
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Pretreatment with chlordiazepoxide (0.64-10 mg/kg) produced a dose-dependent (R=0.93, p<0.05) antagonism of discriminativ~

stimulus produced by PTZ.

WHereas 80% of the rats

pretreated with chlordiazepoxide (CDP) at a dose of 0.64
mg/kg 30 minutes before PTZ (20 mg/kg) injection selected the
PTZ lever, 30 and 20% of the rats selected the PTZ lever after pretreatment with 2.5 and 10 mg/kg CDP.
(0.67-4.96) mg/kg.
emitted

0.4~0.22

The ED50 was 1.8

The rats pretreated with CDP (0.64 mg/kg)

responses with the nonselected lever prior

to lever selection whereas the rats pretreated with CDP (2.5
or 10 mg/kg) did not emit any responses with the nonselected
lever prior to lever selection.

Response rate during the CDP

(8.64-10 mg/kg) antagonism test was not significantly different (One-Way Analysis of Variance, p>0.05)

from rates of re-

sponding during the saline or PTZ sessions preceding the
tests.
Clonazepam (0.04-0.64 mg/kg) pretreatment antagonized
the discriminative stimulus produced by PTZ in a dose-dependent (R=0.96, p<0.05) manner.

Whereas 50% of teh rats pre-

treated with clonazepam at a dose of 0.04 mg/kg 30 minutes
prior to PTZ (20 mg/kg) selected the PTZ lever, 38 and 0% of
the rats pretreated with clonazepam (0.16 and 0.64 mg/kg) selected the PTZ lever.

The ED50 was 0.05 (0.015-0.17) mg/kg.

The rats pretreated with clonazepam (0.04 mg/kg) emitted
0.2+0.16 responses with the nonselected lever prior to lever
selection whereas the rats pretreated with 0.16 and 0.64
mg/kg of clonazepam did not emit any responses with the non-
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selected lever prior to lever selection.

Response rates of

rats pretreated with clonazepam (0.04 mg/kg) were significantly greater (Duncan's Multiple Range Test, p<0.05) than
rates of responding during the preceding saline session but
not significantly different (Duncan's Multiple Range Test,
P>0.05) from rates of responding during the preceding PTZ
session.

Response rates after clonazepam (0.16 and 0.64

mg/kg) pretreatment, however, were not significantly different (F d.f. 2,15=1.45, p>0.05; F d.f. 2,15=1.94, p>0.05) from
rates of responding during the preceding PTZ or saline sessions.
Diazepam (1.25-10 mg/kg) injection 30 minutes prior to
administration of PTZ (20 mg/kg) produced a dose-dependent
(R=0.99, p<0.05) antagonism of the discriminative stimulus
produced by PTZ (20 mg/kg).

Whereas 83% of the rats pre-

treated with diazepam (1.25 mg/kg) selected the PTZ lever,
67, 33 and 17% of the rats selected the PTZ lever after pretreatment with 2.5, 5 and 10 mg/kg of diazepam.
was 3.5 (1.6-8.0) mg/kg.
l.5~1.33,

0.7~0.49

The ED50

These rats emitted 0.8+0.54,

and 2.0+0.77 responses with the nonse-

lected lever prior to lever selection after pretreatment with
diazepam 1.25, 2.5, 5 and 10 mg/kg, respectively.

Response

rate during the diazepam (1.25 mg/kg) antagonism test was
significantly less (Duncan's Multiple Range Test, p<0.05)
than rates of responding during the preceding saline session
but not significantly different (Duncan's Multiple Range Test,
p>0.05) from rates of responding during the preceding PTZ
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session.

Rates of responding after diazepam (2.5 and 5 mg/kg)

pretreatment were not significantly different (F d.f. 2,6=0.47,
P>0.05~

F d.f. 2,15=1.60, P>0.05) from rates of responding

during the saline or PTZ sessions preceding tests with these
doses of diazepam.

However, rates of responding after pre-

treatment with the highest dose of diazepam (10 mg/kg) were
significantly less (Duncan's Multiple Range Test, P<0.05 than
rates of responding during the preceding PTZ and saline sessions.
Clobazam (0.64-40 mg/kg)

30 minutes prior to PTZ (20

mg/kg) antagonized the discriminative stimulus produced by
PTZ in a dose-dependent manner (R=0.99, P<0.05).

Whereas

100% of the rats pretreated with clobazam (0.64 mg/kg) selected the PTZ lever, 83, 33 and 0% of the rats selected the
PTZ lever after treatment with 2.5, 10 and 40 mg/kg clobazam,
respectively.

The ED50 was 6.2 (2.4-16.0) mg/kg.

The rats

pretreated with clobazam (0.64 and 2.5 mg/kg) did not emit
any responses with the nonselected lever prior to lever selection whereas the rats pretreated with 10 and 40 mg/kg
clobazam emitted

0.2~0.17

responses with the nonselected

lever prior to lever selection.

Response rates during the

clobazam (2.5 and 40 mg/kg) antagonism tests were not significantly different (F d.f. 2,5=1.61, p>0.05; F d.f. 2,9=
2.05, p>0.05) from rates of responding during the saline or
PTZ sessions preceding the tests.

Response rates after

clobazam (10 mg/kg) was significantly less (Duncan's Multiple Range Test, p<0.05) than rate of responding during
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the preceding saline session but not significantly different
(Duncan's Multiple Range Test, p>0.05) from rates of responding

du~ing

the preceding PTZ session.

Flurazepam (1.25-20 mg/kg) antagonized the PTZ discriminative stimulus in dose-dependent fashion (R=0.96, p<0.05).
Whereas 100% of the rats pretreated with flurazepam (1.25
mg/kg)

30 minutes before PTZ (20 mg/kg) selected the PTZ

lever, 50 and 33% of the rats selected the PTZ lever after
pretreatment with 5 and 20 mg/kg flurazepam.
8.6 (3.1-13.7) mg/kg.
emitted 0.3+0.25,

The ED50 was

The rats pretreated with flurazepam

0.2~0.17

and zero responses with the non-

selected lever prior to lever selection after 1.25, 5 and 20
mg/kg flurazepam, respectively.

Rate of responding of rats

pretreated with flurazepam (1.25 mg/kg) was significantly
greater (Duncan's Multiple Range Test, p<0.05) than rate of
responding during the preceding saline session but not significantly different (Duncan's Multiple Range Test, p>0.05)
from response rate during the preceding PTZ session.
flurazeparn (5 mg/kg) pretreatment the rats emitted
sponses.

After

963~78

re-

This was not significantly different (F.d. f .2,15=

1.36, p>0.05) from the 1105+57 emitted during the preceding
saline session or the

963~74

responses that were emitted dur-

ing the preceding PTZ sessions.

Response rate after fluraze-

pam (20 mg/kg) pretreatment, however, was significantly less
(Duncan's Multiple Range Test, p<0.05) than rate of responding during the preceding PTZ and saline sessions.
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Meprobamate (5-80 mg/kg) antagonized the PTZ discriminative stimulus in a dose-dependent (R=0.98, p<0.05) manner.
Whereas 100% of the rats treated with meprobamate (5 mg/kg)
30 minutes prior to PTZ (20 mg/kg) selected the PTZ lever,
67 and 0% of the rats injected with meprobamate 20 and 80
mg/kg selected the PTZ lever.
mg/kg.

The ED50 was 22.5 (16.6-30.7

The rats treated with meprobamate 5 and 80 mg/kg

emitted 0.2+0.17 responses with the nonselected lever prior
to lever selection whereas the rats treated with 20 mg/kg
meprobamate did not emit any responses with nonselected lever before lever selection.

Response rates after meproba-

mate (5-80 mg/kg) pretreatment were significantly less (Duncan's Multiple Range Test, p<0.05) than rates of responding
during the preceding saline sessions but not significantly
different (Duncan's Multiple Range Test, p>0.05)

from re-

sponse rates during the preceding PTZ sessions.
Pentobarbital (2.5-10 mg/kg) pretreatment dose-dependently (R=0.98, p<0.05) antagonized the discriminative stimulus produced by PTZ (20 mg/kg).

Whereas 100% of the rats

treated with pentobarbital (2.5 mg/kg)

30 minutes before PTZ

(20 mg/kg) selected the PTZ lever, 33 and 0% selected the
PTZ lever after pretreatment with 5 and 10 mg/kg pentobarbital, respectively.

These rats emitted 2.0+l.98 zero and

0.9+0.80 responses with the nonselected lever prior to lever
selection after pretreatment with pentobarbital.

Response

rates during the pentobarbital (2.5-10 mg/kg) test sessions
were not significantly different (F d.f. 2,15=3.21, p>0.05;
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F d.f. 2,15=0.0l, p>0.05; F d.f. 2,15=0.76, p>0.05) from
rates of responding during the saline or PTZ sessions preceding the pentobarbital antagonism tests.
Phenobarbital (2.5-40 mg/kg) treatment .30 minutes prior
to PTZ (20 .:mg/kg) produced a dose-dependent (R=l.00, p<0.05)
antagonism of the PTZ discriminate stimulus.

Whereas 100%

of the rats pretrreated with 2.5 mg/kg phenobarbital selected
the PTZ lever, 50 and 0% of the rats pretreated with 10 and
40 mg/kg phenobarbital selected the PTZ lever.
10 (7.4-13.5) mg/kg.

The ED50 was

The rats pretreated with 2.5 and 40

mg/kg phenobarbital emitted

0.7~~.42

responses with the non-

selected lever before lever selection whereas the rats pretreated with 10 mg/kg phenobarbital emitted zero responses
with the nonselected lever prior to lever selection.

Rates

of responding after pretreatment with phenobarbital (2.5 and
10 mg/kg) were not significantly different (F d.f. 2,12=1.43,
p>9.05, F d.f. 2,12=3.29, p>0.05) from rates of responding
during the PTZ or saline sessions preceding these phenobarbital antagonism tests.

After pretreatment with 40 mg/kg

phenobarbital the rats emitted 632+91 responses.

This was

significantly less (Duncan's Multiple Range Test, p<0.05)
than 966+63 responses that were emitted during the preceding
saline session but not significantly different (Duncan's
Multiple Range Test, p 0.05)>from 778+94 responses emitted
during the preceding PTZ session.
2.

Effect of Non-Anxiolytic Anticonvu1s·a nt Drugs
Trimethadione (TMD) failed to significantly (Fisher
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Exact Probability, P>0.05) antagonize the discriminative stimulus produced by PTZ.
treate~

Seventy-eight percent of the rats pre-

with TMD (160 mg/kg)

selected the PTZ lever when TMD

was administered 30 minutes before PTZ (20 mg/kg) and 67% of
six rats selected the PTZ lever after 320 mg/kg TMD pretreatment.

Two rats pretreated with the latter dose of TMD did

not make a lever selection.

After TMD 160 and 320 mg/kg pre-

treatment the rats making a lever selection emitted 0.3+0.24
and

2.0~l.29

responses, respectively, with the nonselected

lever prior to lever selection.

On the TMD (160 mg/kg) test

session the rats emitted 553+54 responses.

This was signif-

icantly less (Duncan's Multiple Range Test, p<0.05) than the
803~71

responses emitted during the preceding saline session

but not significantly different (Duncan's Multiple Range
Test, p>0.05) from

623~75

ceding PTZ session.

responses emitted during the pre-

During the TMD (320 mg/kg) test ses-

sion, however, rate of responding was significantly less
(Duncan's Multiple Range Test, P<0.05) than response rate
during the preceding PTZ and saline sessions.
Ethosuximide (100-200 mg/kg) treatment 30 minutes prior
to injection of PTZ (20 mg/kg) failed to significantly
(Fisher Exact Probability, p>0.05) antagonize the PTZ discriminative stimulus.

Seventy-eight percent of the rats

pretreated with ethosuximide (100 mg/kg) selected the PTZ
lever and 100% of the rats injected with 200 mg/kg ethosuximide selected the PTZ lever.

Two rats pretreated with the
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highest dose of ethosuximide did not make a lever selection .
The rats pretreated with 100 mg/kg ethosuximide emitted 0.9+
0.51 responses with the nonselected lever prior to lever selection, whereas the rats pretreated with 200 mg/kg ethosuximide that made a lever selection emitted

0.4~0.29

responses

with the saline lever prior to PTZ lever selection.

Response

rates during the ethosuximide (100 and 200 mg/kg) test sessions were significantly less

(Duncan's Multiple Range Test,

p<0.05) than rates of responding during the preceding PTZ
and saline sessions.
Diphenylhydantoin (30-60 mg/kg) administered 15 minutes
before injection of PTZ (20 mg/kg) failed to significantly
(Fisher Exact Probability, p>0.05) antagonize the PTZ discriminative stimulus.

Eighty-three percent of the rats pre-

treated with either 30 or 60 mg/kg diphenylhydantoin (DPH)
selected the PTZ lever.

Zero and

0.2~0.17

responses were

emitted with the nonselected lever prior to lever selection
during the test sessions when the rats were pretreated with
30 and 60 mg/kg (DPH), respectively.

Response rates during

the antagonism test sessions were significantly less (Duncan's Multiple Range Test, p<0.05) than response rates during the saline and PTZ sessions preceding the tests.
3.

Effect of Some GABAmimetic Drugs
Treatment of rats trained to discriminate PTZ (20

mg/kg) from saline with valproic acid (40-320 mg/kg) produced a dose-dependent (R=0.98, p<0.05) antagonism of PTZ
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discriminative stimulus.

Whereas 100% of the rats treated

with valproic acid (40 mg/kg) selected the PTZ lever, 75 and
33% of . the animals selected the PTZ lever after pretreatment
with 160 and 320 mg/kg valproic acid, respectively.
was 244 (156-382) mg/kg.

The EDSO

Three rats pretreated with 640 mg/kg

valproic acid did not make a lever selection.

Rats pre-

treated with 40 mg/kg valproic acid did not emit any responses
with the saline lever prior to PTZ lever selection whereas the
rats pretreated with 160 and 320 mg/kg valproic acid emitted
0.4+0.26 and 0.7±0.49 responses with the incorrect lever prior
to lever selection.

Rats pretreated with valproic acid (160

mg/kg) emitted 600±59 responses during this valproic acid
test session.

This was significantly less (Duncan's Multiple

Range Test, p<0.05) than 903±80 responses emitted during the
preceding saline session but not significantly different
(Duncan's Multiple Range Test, p>0.05) from 614±80 responses
emitted during the preceding PTZ session.

Response rate dur-

ing the valproic acid (320 mg/kg) test session, however, was
significantly less (Duncan's Multiple Range Test, p<0.05)
than rates of responding during the preceding PTZ and saline
sessions.
Administration of etomidate sulfate (5 -mg/k.g) 5 minutes
before injection of PTZ (20 mg/kg) failed to significantly
(Fisher Exact Probability, p>0.05} antagonize the PTZ discriminative stimulus.

Eighty-three percent of the rats

treated with this dose of etomidate selected the PTZ lever.

78

The rats pretreated with etomidate (5 mg/kg) emitted

l.2~1.17

responses with the nonselected lever prior to lever selection.
Five

o~t

of six rats treated with etomidate (10 mg/kg) 5 min-

utes before PTZ (20 mg/kg) did not make a lever selection. The
one rat that made a lever selection selected the PTZ lever and
emitted one response with the saline lever before PTZ lever
selection.

The rats emitted

date (5 mg/kg) test session.

793~77

responses during the etomi-

This was significantly less

(Duncan's Multiple Range Test, p<0.05) than 1087+50 responses
emitted during the preceding saline session but not significantly different (Duncan's Multiple Range Test, p>0.05) from
810+49 responses ewitted during the preceding PTZ

session ~ .

Treatment of rats with etomidate (10 and 40 mg/kg) two
hours before PTZ (20 mg/kg) injection also failed to antagonize the discriminative stimulus produced by PTZ.

All of

the rats pretreated with 10 mg/kg etomidate and tested 2
hours later for lever selection selected the PTZ lever. These
rats emitted 0.8+0.48 responses with the saline lever before
PTZ lever selection.

Response rate during this test session

was significantly different (Duncan's Multiple Range Test,
p

0~05)

from rates of responding during the preceding PTZ and

saline sessions.

After a 40 mg/kg etomidate injection two

out of four rats selected the PTZ lever and two selected the
saline lever.

This was not significantly different (Fisher

Exact Probability, p>0.05) from 100% PTZ lever selection
after PTZ (20 mg/kg).

These rats emitted 2.0+1.68 responses

79

with the nonselected lever prior to lever selection.

Two rats

did not make a lever selection after pretreatment with 40
mg/kg etomidate.

Response rate during the etomidate (40 mg/

kg) test session was significantly different (Duncan's Multiple Range Test, p<0.05) from response rates during the preceding PTZ and saline sessions.
Garnrna-hydroxybutyrate (GHB) treatment 7 minutes prior to
PTZ (20 mg/kg)

injection failed to antagonize the PTZ dis-

criminative stimulus.

One hundred percent of the rats pre-

treated with GHB (80-160 mg/kg) selected the PTZ lever.
These rats emitted l.3+0.95 and 0.5+0.29 responses with the
saline lever before PTZ lever selection.

Response rates dur-

ing the GHB antagonism tests were not significantly different
(F d.f. 2,9=1.65, p>0.05; F d.f. 2,9=1.86, p>0.05)

from re-

sponse rates during the PTZ and saline sessions preceding
these tests.

Four rats pretreated with 320 mg/kg GHB did

not make a lever selection.
Administration of garnma-acetylenic GABA (100 mg/kg)
hours prior to PTZ (20 mg/kg)

2-24

injection did not significantly

(Fisher Exact Probability, p<0.05) antagonize the discriminative stimulus produced by PTZ.

When tested for lever selec-

tion 2, 4, 8 and 24 hours after gamma-acetylenic GABA (GAG),
80, 100, 100 and 86% of the rats making a lever selection selected the PTZ lever.

These rats emitted zero,

0.4~0.40,

0.5+0.50 and l.4+0.81 responses with the nonselected lever
prior to lever selection.

Response rates during all GAG
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antagonism tests were significantly lower (Duncan's Multiple
T~st,

Range

p<0.05) than response rates during the PTZ and

saline ·sessions preceding these tests.

One, two and four rats

tested for lever selection at four, eight and 24 hours after
GAG did not make a lever selection.
Gamma vinyl GABA (1000 mg/kg) did not angagonize the
PTZ discriminative stimulus when the rats were tested for lever selection 72 hours after gamma-vinyl GABA (GVG) injection.
Three out of four rats tested at this time selected the PTZ
lever and these rats did not emit any responses with the saline lever before PTZ lever selection.
a lever selection.

One rat did not make

When tested at 2 and 8 hours after GVG

the rats did not make a lever selection.

One rat selected

the PTZ lever when tested 24 hours after GVG, seven rats did
not make a lever selection.

Response rate for the three rats

making a lever selection 72 hours after GVG was significantly
less (Duncan's Multiple Range Test, p<0.05) than the rate of
responding of these rats during the preceding PTZ and saline
sessions.

4.

Other CNS Depressants
Ethanol (250-1000 mg/kg) treatment 15 minutes prior

to injection of PTZ (20 mg/kg)

failed to antagonize the dis-

criminative stimulus produced by PTZ.

All of the rats pre-

treated with ethanol selected the PTZ lever and these rats
did not emit any responses with the saline lever before PTZ
lever selection.

Two rats pretreated with 1000 mg/kg ethanol
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did not make a lever selection.

Response rates during the

ethanol test sessions were significantly less (Duncan's Multiple Range Test, P<0.05) than rates of responding during the
saline sessions preceding the tests but not significantly different (Duncan's Multiple Range Test,

p ~ 0.05)

from response

rates during the PTZ sessions preceding the tests.
Morphine (10 mg/kg) pretreatment did not antagonize the
PTZ discriminative stimulus when administered 15 minutes
prior to PTZ (20 mg/kg).

Three of eight rats that made a

lever selection selected the PTZ lever and these rats emitted
0.7~0.67

responses with the saline lever prior to PTZ lever

selection.

Response rate during the morphine antagonism test

session was significantly less (Duncan's Multiple Range Test,
p<0.05) than rate of responding during the preceding PTZ and
saline sessions.

5.

Effect of Caffeine:

A

Phosphodi~sterase

Inhibitor

Eighty percent of five rats treated with caffeine
(20 mg/kg)

30 minutes before PTZ (20 mg/kg) injection selected

the PTZ lever (Fisher Ex act Probability, p >0.05).
emitted

0.4~0.24

These rats

responses with the nonselected lever prior

to lever selection.

Response rate during the caffeine antag-

onism test session was not significantly different (F.d.
f.2,9=1.05, p>0.05) £rom rate 0£ responding during the preceding PTZ or saline sessions.
6.

Effect 0£ Drugs A££ecting Catec·holaminergic Trans-

mission.
Clonidine (0.04-0.64

mg/kg) treatment 30 minutes
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before injection of PTZ (20 mg/kg) failed to antagonize the
discriminative stimulus produced by PTZ.

All of the rats

pretreated with these doses of clonidine selected the PTZ
lever.

Three rats pretreated with 0.64 mg/kg clonidine did

not make a lever selection.
the rats emitted

0.8~0.75

After 0.04 mg/kg pretreatment

responses with the saline lever be-

fore PTZ lever selection and after 0.16 mg/kg clonidine pretreatment the rats emitted

l.8~0.97

responses with the sa-

line lever be£ore PTZ lever selection.

Response rates dur-

ing the clonidine test sessions were significantly less
(Duncan's Multiple Range Test, P<0.05) than the rate 0£ responding during the PTZ and saline sessions preceding the
clonidine antagonism tests.
Propranolol (10 mg/kg) pretreatment did not signi£icantly (Fisher Exact Probability,
criminative stimulus.

p~~ ..

05) antagonize the PTZ dis-

Eighty percent of five rats pretreated

with propranol selected the PTZ lever and these rats did not
emit any responses with the nonselected
selection.

leve~

prior to lever

During the propranol test session the rats emit-

ted 588+121 responses.

This was significantly less (Duncan's

Multiple Range Test, p<0.05) than the

1008~66

responses

emitted during the saline session preceding the test but not
significantly di£ferent (Duncan's Multiple Range Test, p>0.05)
from 668+97 responses emitted during the PTZ preceding the
test.
Aceperone (0.64 or 2.5 mg/kg) did not antagonize the PTZ
discriminative stimulus.

All of four rats pretreated with
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Haloperidol (0.16-0.64 mg/kg) also failed to antagonize
the discriminative stimulus produced by PTZ.
treatep with haloperidol (0.16 mg/kg)
(20 mg/kg)

ALl of six rats

30 minutes prior to PTZ

injection selected the PTZ lever.

These rats

emitted 0.4+0.33 responses with the saline lever before selection of the PTZ lever.

During the haloperidol (0.16 mg/kg)

test session the rats emitted

265~97

responses.

This was sig-

nificantly less (Duncan's Multiple Range Test, p<0.05) than
the 975+86 and 1132+71 responses that were emitted during the
PTZ and saline sessions preceding the haloperidol antagonism
test.
Of two rats pretreated with 0.64 mg/kg haloperidol, one
rat did not make a lever selection and the other rat selected
the PTZ lever.

7.

Effect of Drugs Affecting Serotonergic Transmission
Five rats treated with methysergide (2.5 mg/kg)

30

minutes before injection of PTZ (20 mg/kg) selected the PTZ
lever.

These rats emitted 3.4+1.67 responses with the saline

lever before PTZ lever selection.

Response rate during the

methysergide antagonism test session was significantly different (Duncan's Multiple Range Test, p<0.05) from response
rate during the saline session preceding the test but not
significantly different (Duncan's Multiple Range Test, p>0.05)
from response rate during the PTZ session preceding the test.
Fluoxetine (5-10 mg/kg) treatment 15 minutes before injection of PTZ · (20 mg/kg)

failed to antagonize the discrimi-
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native stimulus produced by PTZ.

All of the rats pretreated

with these doses of fluoxetine selected the PTZ lever and
these rats did not emit any responses with the saline before
selection of the PTZ lever.

Response rate during the fluoxe-

tine antagonism test sessions were significantly less (Duncan's Multiple Range Test, p<0.05) than response rate during
the PTZ and saline sessions preceding the tests.
Amitriptyline (10-20 mg/kg)

injection 30 minutes before

PTZ (20 mg/kg) did not block the PTZ discriminative stimulus.
All of six rats pretreated with 10 mg/kg amitriptyline selected the PTZ lever and these rats emitted l.8+0.87 responses with the saline lever before PTZ lever selection.
These rats emitted 213±75 responses during this amitriptyline
test session.

This was significantly less (Duncan's Multiple

Range Test, p<0.05) than the 410±72 and 853±80 responses that
were emitted during the PTZ and saline sessions preceding the
tests.

After 20 mg/kg amitriptyline pretreatment three rats

did not make a lever selection while two selected the PTZ
lever.

The two rats that made a lever selection emitted an

average of one response on the saline lever before selection
of · the PTZ lever.

Response rate of these two rats appeared

to be decreased compared to response rate during the PTZ and
saline sessions preceding the test.
Treatment with R04-4602 plus DL-5-hydroxytryptophan
(100 mg/kg) one hour before PTZ (20 mg/kg) injection did not
antagonize the discriminative stimulus produced by PTZ.
of the rats pretreated with R04-4602 plus

All

DL~S-hydroxytryp-
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tophan (5-HTP) selected the PTZ lever and these did not emit
any responses with the saline lever before selection of the
PTZ lever.

Response rate during the 5-HTP antagonism test

session was significantly less (Duncan's Multiple Range Test,
p<0.05) than response rate during the PTZ and saline sessions
preceding the R04-4602 + 5-HTP tests.

8.

Effect of Anticholinergics
Scopolamine (0.64 mg/kg)

injection of PTZ (20 mg/kg)
Exact Probability, p>0.05)
stimulus.

treatment 15 minutes before

did not significantly (Fisher
antagonize the PTZ discriminative

Eighty-four percent of six rats selected the PTZ

lever while one rat did not make a lever selection.
that made a lever selection emitted

l.0~0.63

The rats

responses with

the nonselected lever prior to lever selection.

During the

scopolamine antagonism test the animals emitted 124+70 responses.

This was significantly less (Duncan's Multiple

Range Test, p<0.05)

than the 906+67 and 1166+54 responses

that were emitted during the PTZ and saline sessions preceding the test.
Atropine (5-10 mg/kg) also failed to antagonize the PTZ
discriminative stimulus.

All of four rats treated with 5

mg/kg atropine 30 minutes before injection of pTZ (20 mg/kg)
selected the PTZ lever and these rats did not emit any responses with the saline lever before PTZ lever selection.
Response rate of these rats during the test session was significantly less (Duncan's Multiple Range Test, p<0.05) than
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TABLE 5.

Antagonism tests with rats trained to discriminate between
pentylenetetrazol (20 mg/kg) and saline. l

Test Drug

ACEPERONE

Dose
(mg/kg)

0.64
2.5

Pretreatment
Time
(Minutes)

2
N

30

4
5

% Selecting
PTZ Lever3

100
80

AMITRIPTYLINE
HYDROCHLORIDE

10
20

30

6
2
3

100
100
No Selection

ATROPINE SULFATE

5

30

4
1
2

100
No Selection
100

10

4
Mean Responses ~·
(+S.E.)on NonSelected Lever
Before Lever
Selection

0.75+0.75
0.20+0.20
1.8+0 .87
1.0

0
0.5

CAFFEINE CITRATE

20

30

5

80

0.4+0.24

CHLORDIAZEPOXIDE
HYDROCHLORIDE

0.64
2.5
10

30

10

80
30
20

0.4+0.22
0
0

1. 25
5

30

4
4

0.64
2.5
10
40

30

6
6
6
5

100
83
33
0

0
0
0.2+0.17
0.2+0.17

CLONAZEPAM

0.04
0.16
0.64

30

6
6
8

50
33
0

0.2+0.16
0
0

CLONIDINE
HYDROCHLORIDE

0.04
0.16
0.64

30

4
5
1
3

1.25
2.5
5
10

30

6
6
6
6

CHLORPROMAZI NE

CLOBAZAM

DIAZEPAM

10

10

100
No Selection

100
100
100
No Selection
83
67
33
17

0

0.8+0.75
1.8+0. 97
0

0.8+0.54
1. 5+1. 33
0.7+0.49
2. o+o. 77
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TABLE 5 continued

4

Test Drug

DIPHENYLHYDAN'IDIN

ETHANOL

ETHOSUXIMIDE

ETOMIDATE SULFATE

FLUOXETINE

FLURAZEPAM
DI HYDROCHLORIDE

GAMMA-ACETYLENIC
GAMA

Dose
(mg/kg)

Pretreatment
Time
2
(Minutes) ... N

15

6
6

250
1000

15

3
4
2

100
100
No Selection

100
200

30

9
5
2

78
100
No Selection

0;9+0.51
0.4+0.24

5
10

5

2 h

83
100
No Selection
100
50
No Selection

l.2+1.17
1.0

10
40

6
1
5
4
4
2

5
10

15

3
4

100
100

0
0

1.25
5
20

30

6

100
50
33

0.3+0.25
0.2+0.17
0

100

2 h
4 h

6

6

24 h

80
160
320

7

83
83

0
0.2+0.17

30
60

8 h

GAMMA-HYDROXYBUTYRATE

Mean Responses
( +S .E.) on NonSelected Lever
% Selecting Before Lever
-PTZ -Lever3 . SeJ.~ct;i.on

5
5
1
4
2
7
4

80
100
100
100
No Selection
86
No Selection

4
4

100
100
No Selection

4

0
0

0.8+Q.48
2;0+1.68

0
OA+0.40
0.5+0.50
0.5+0.50
1.4+0 .81

1 -. 3+0. 95
0~5+0.29
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TABLE 5 continued

Test Drug

GAMMA-VINYL GABA

Dose
(mg/kg)

1000

Pretrea trnent
Time
(Minutes)

2
8
24
72

HALOPERIDOL

0.16
0.64

45

2
N

% Selecting
PTZ Lever3

4
4
1
7
3
1

No Selection
No Selection
100
No Selection
100
No Selection

6

100
100
No Selection

1

1

Mean Responses
( +S .E.) on NonSelected Lever
Before Lever
Selection

0
0

0.4+0.33
0

5
20
80

30

6
6
6

100
67
0

0.2+0.17
0
0.2+0.17

2.5

30

5

100

3.4+1.67

10

15

3
5

100
No Selection

0.7+0.67

PENTOBARBITAL

2.5
5
10

20

6
6
6

100
33
0

2.0+1.48
0
0.9+0.8

PHENOBARBITAL

2.5
10
40

45

5
6
6

100
50
0

0.7+0.42
0
0.7+0.42

10

30

5

80

0

1 h
30

4

100

0

15-60

14

100

0.5+0.37

MEPROBAMA'J'E

METHYSERGIDE
MORPHINE SULFATE

PROPRANOLOL
R04-4602+DL-5HYDROXYTRYPTOPHAN

25
100

SALINE
SCOPOLAMINE HYDROBROMIDE

TRIMETHADIONE

0.64

15

6
1

84
No Selection

l.0+0.63

160
320

30

9
6
2

78
67
No Selection

0.3+0.24
2 •. 0j:.1 ~ 29

........

4

TABLE 5 continued

Test Drug

90

Dose
(mg/kg)

1% '!WEEN 80 +
13% PROPYLENE
GLYCOL
VALPROIC ACID

40
160
320
640

Mean Responses
( +s . E • ) on Non Pretreatment
% Selecting Selected Lever
Time
2
N PTZ Lever3 Before Lever
(Minutes)
Selection

30

10

45

6
8
6

3

100

0.3+0.29

0
100
0.4+0.26
75
0.7+0.49
33
No Selection

1

Following pretreatment with the test drug, the rats were injected with
pentylenetetrazol (20 mg/kg). 15 min following the pentylenetetrazol
injection, animals were placed in the.ir assigned Skinner box and allowed
to make a lever selection. The lever with which ten responses were completed first was considered the selected lever.
2

Number of rats tested.

3

% of rats selecting the pentylenetetrazol lever.
"No selection" indicates that ten responses were not completed on either lever in the 10
min session due to behavioral toxicity of the drugs.
4

Responses (Mean~S.E.) emitted with nonselected lever before lever selection. Where N < 3 mean is given.

4

TABLE 6.

Antagonism Tests: Effect of Test Drugs on Response Rate in Rats Trained to Discriminate
Between Pentylenetetrazol and Saline

Test Drug

ACEPERONE

AMITRYPTYLINE
HYDROCHLORIDE

ATROPINE SULFATE

CAFFEINE
CHLORDIAZEPOXIDE
HYDROCHLORIDE

CHLORPROMAZINE

CLO BA ZAM

Dose
(mg/kg)

Pretrea trnent
Time
(Minutes)

0.64
2.50

30

10
20

30

Responses/10 Min3
Mean+S.E.
-· - -- - · -N2

PTZ

Saline

% + S.E.

Test
Drug

% PTZ

4

% Saline

4
5

895+72
444+69

1125+80
858+70

615+76
422+63

68+5
95+4

54+4
48+4

6
2
3

410+72
725
200+90

853+80
1325
590+171

213+75
70
0

51+13
10
0

24+6
6
0

-

-

-

-

-

-

-

5

30

4
1
2

543+58
290
360

843+74
960
655

157+34
0
95

28+5
0
26

18+3
0
19

20

30

5

385+117

-

668+170

-

543+120

163+25

85+18

o. 64

30

10
10
10

660+56
709+48
807+95

809+61
880+58
951+90

703+45
767+60
776+58

2.5
10
1.25
5

30

2.5
10
40

30

-

-

-

-

4
4

443+94
638+105

620+21
1080+125

258+31
0

6
6
5

885+82
872+100
728+116

1072+83
1138+63
853+94

858+108
907+50
540+134

-

-

-

-

-

111+7
108+5
100+7

-

-

90+6
88+4
84+7

-

68+18
0

45+16
-0

102+21
112+16
88+36

83+14
80+3
64+14

-

-

\D

......

TABLE 6 continued
I

Test Drug

CLONAZEPAM

CLONIDINE
HYDROCHLORIDE

DIAZEPAM

DIPHENYLHYDANTOIN

ETHANOL

ETHOSUXIMIDE

Dose
(mg/kg)

Pretreatment
Time
(Minutes)

0.04
0.16
0.64

30

0.04
0.16
0.64

30

1.25
2.5
5
10

30

30
60

15

250
1000

100
200

Responses/10 Min
Mean±..S .E.
2
N

PTZ

6
6
6

513+95
492+75
457+73

6
5
1
3

678+162
782+48
830
663+157

6
6
6
6

-

-

1002+47
743+48
827+42
933+84

-

3

% + S.E.

4

Test
Dru9

% PTZ

702+99
610+81
595+80

145+19
128+13
139+17

743+55
1106+63
950
1197+81

210+63
56+22
60
0

33+10
7+3
7
0

1178+49
757+67
983+99
1073+66

903+87
820+62
827+62
588+154

91+8
114+7
101+8
65+19

76+7
110+12
90+13
53+13

332+75
267+101

52+12
40+17

33+7
34+13

Saline

987+69
655+50
700+106

-

-

973+100
865+148

-

-

-

% Saline

73+11
91+9
89+10

-

28+7
5+2
6
0

-

6
6

770+149
690+90

15

3
4
2

553+60
630+172
595

907+38
893+49
1025

500+110
300+46
0

93+25
67+24
0

56+14
33+4
0

30

9
5
2

747+92
768+125
560

1001+111
913+132
675

643+91
325+91
-0

84+4
49+18
-0

64+7
41+15
0

-

-

-

-

l.O

""

TABLE 6 continued

Test Drug

E'IOMIDATE
SULFATE

FLUOXETINE

FLURAZEPAM
DIHYDROCHLORIDE

GAMMA-ACETYLENIC
GABA

Dose
(mg/kg)

Pretreatment
Time
N2
(Minutes)

5
10

5

10
40

2 h

5
10

15

1.25
5
20

30

100

2 h
4 h
8 h
24 h

GAMMA-HYDROXYBUTYRATE

80
160
320

7

Responses/10 Min
Mean + S.E.
PTZ

3

Saline

% + S.E.

Test
Drug

4

% PTZ

% Saline

6
1
5
4
4
2

810+49
380
320+90
595+115
648+96
· 295

1087+50
990
708+164
870+310
773+68
780

793+77
310
0
125+55
243+159
0

99+9
82
0
20+5
40+24
0

73+6
31
0
14+7
29+18
0

3
4

893+74
810+86

1240+29
1128+54

730+15
370+97

83+5
44+9

59+1
32+7

6
6
6

480+83
963+74
1053+33

860+89
1105+57
990+33

625+24
963+78
845+52

148+34
100+4
80+3

76+9
87+4
86+7

5
5
1
4
2
7
4

1046+97
906+62
890
1085+85
710
927+109
1225

1116+59
1048+83
1000
1203+110
1180
1110+101
1125

195+125
214+112
0
610+206
0
400+91
0

22+13
22+10
0
61+23
0
46+15
0

18+10
23+13
0
57+22
-0
38+12
0

4
4
4

615+199
538+160
810+390

923+130
660+155
775+275

548+127
328+94
0

96+9
75+18
0

58+7
47+5
0

-

-

-

-

I

-

-

-

-

-

-

-

l.D

w

TABLE 6 continued

Responses/10 Min 3
Mean+S.E.

Test Drug
GAMMA-VINYL

Dose
(mg/kg)
1000

GABA

Pretrea tlnent
Time
(Minutes)
4 h
8 h
24 h
72 h

% + S.E.

4

-

N2

4
4
1
7
3
1

PTZ
658+112
717+31
730
681+63
807+168
350

Saline

Test
Drug

% PTZ

% Saline

975+106
1102+39
670
1091+27
963+149
1010

0
0
260
0
320+25
0

0
0
36
0
41+8
0

1132+71
1160

265+97
80

30+12
7

25+10
7

1097+46
1043+55
1132"+47

618+76
795+79
872+59

90+7
101+11
122+21

56+6
78+9
78+4

0
0
39
0
34+3
0

HALOPERIOOL

0.16
0.64

45

6
1

MEPROBAMATE

5
20
80

30

6
6
6

733+125
803+45
798+112

2.5

30

5

508+83

-

606+76

-

366+62

-

74+10

62+11

10

15

3
5

676+102
502+96

980+98
966+97

223+74
0

36+14
0

24+10
0

6
6
6

901+44
813+98
733+74

1060+43
822+135
890+105

997+46
837+97
817+88

111+5
103+6
113+11

6
6
6

784+142
596+137
778+94

708+137
740+100
632+91

92+6
138+19
81+4

ME THY SERGI DE
IDRPHINE
SULFATE
PENTOBARBITAL

PHENOBARBITAL

2.5
5
10

20

2.5
10
10

30

975+86
1120

-

-

-

-

-

-

-

988+81
976+75
966+63

-

-

-

-

-

-

-

94+2
107+9
93+5
70+11
75+7
65+5

-

ID
.t.

TABLE 6 continued

Test Drug

3
% + S.E.

4

Dose
(mg/kg)

Pretreatment
Time
(Minutes)

N2

PTZ

Saline

10

30

5

668+97

-

1008+66

588+121

-

88+12

-

54+12

1 h
30

t' ,

838+54

1233+73

-

330+68

-

39+6

27+5

975+155

815+124

-

107+3

86+12

124+70
0

14+8
0

11+6
0

553+54
305+76
0

104+20
46+9
0

72+8
37+7
0

PROPRANOLOL
R04-4602-DL-5HYDROXYTRYPTOPHAN

4

Te::;i:

-

Drug

% PTZ

% Saline

-

, ,

-

-

--

15-60

0.64

15

6
1

906+67
900

160
320

30

9
6
2

623+75
602+74
685

-

30

7

941+59

1243+30

941+81

103+10

75+6

160
320
640

45

8
6
3

614+80
885+53
830+147

903+80
1080+88
927+178

600+59
380+34
0+0

111+20
44+4
o+o

73+14
36+4
o+o

SALINE
SCOPOLAMINE
HYDRO BROMIDE

Responses/10 Min
Mean+S.E.

TRIMETHADIONE

1% '!WEEN 80
+ 13% PROPYLENE
GLYCOL

VALPROIC ACID

14

755+102

-

-

-

-

1166+54
1030
803+71
783+110
900

-

-

-

1

Test Drugs were administered intraperitoneally. Following pretreatment with the test drug the
rats were placed in their assigned Skinner box and allowed to respond with the levers for 10 min.
2

Number of rats tested.

\0
V1

TABLE 6 continued

3Total responses (mean.2:._S.E.) emitted during the 10 min session following pretreatment with the
test drug and during the preceding pentylenetetrazol (20 mg/kg) and saline session.
4

values were obtained by dividing the total number of lever presses emitted following test
drug pretreatment by the total number of respons.e s during the preceding pentylenetetrazol
(20 mg/kg) and saline session.

l.O

O'

response rate during the PTZ and saline sessions preceding the
test session.

One rat did not make a lever selection after

pretreatment with 5 mg/kg atropine.

Two rats pretreated with

10 mg/kg atropine selected the PTZ lever and these rats did
not emit any responses with the saline lever before PTZ lever
selection.

Response rate during the 10 mg/kg atropine test

session appeared to be decreased compared to the response
rate during the PTZ and saline sessions preceding the test
but the small number of animals prohibited statistical analysis.

Lack of Tolerance Development to Diazepam and Chlordiazepoxide in Antagonism of the PTZ Discriminative Stimulus (Table 7)
Chronic administration of solvent, diazepam or CDP to
rats tested acutely with these drugs for antagonism of the
PTZ discriminative stimulus did not alter their ability to
antagonize the discriminative stimulus produced by PTZ.

All

of the rats pretreated acutely with solvent for antagonism of
the PTZ discriminative stimulus selected the PTZ lever after
chronic solvent administration.

Whereas 67 and 17% of the

rats pretreated acutely for antagonism of the PTZ discriminative stimulus with 2.5 and 10 mg/kg diazepam selected the
PTZ lever, 67 and 33% of these rats selected the PTZ lever
after chronic diazepam administration.

Similarly, whereas

30 and 20% of the rats pretreated acutely for antagonism of
the PTZ discriminative stimulus with 2.5 and 10 mg/kg CDP

98
selected the PTZ lever, 40 and 20% of these rats selected the
PTZ lever after chronic CDP treatment.

Tests for Diazepam and Haloperidol Antagonism of the Discriminative Stimuli Produced by Cocaine, Yohimbine and R05-3663
in Rats Trained to Discriminate Between Pentylenetetrazol
(20 mg/kg) and saline (Tables 8 and 9).
1.

Cocaine
As stated previously (Table 3) , 86% of the rats in-

jected with cocaine (20 mg/kg) selected the PTZ lever when
tested for lever selection 15 min after the cocaine injection.

Diazepam (5 mg/kg) produced a significant (Fisher

Exact Probability, p<0.05) antagonism of the discriminative
stimulus produced by cocaine as only 17% of the rats selected the PTZ lever when cocaine (20 mg/kg) was preceded by
a diazepam (5 mg/kg) injection.
the rats emitted

2.3~1.43

Prior to lever selection

responses with the nonselected

lever. During the diazepam plus cocaine test session the
rats emitted

223~93

responses.

This was significantly less

(Duncan's Multiple Range Test, p<0.05) than the 5532:_88 responses that were emitted by these rats during the PTZ session preceding this test and the 658+87 responses that were
emitted during the saline session preceding the test.
Haloperidol (0.16 mg/kg) did not significantly (Fisher
Exact Probability, p 0.05) antagonize the discriminative
stimulus produced by cocaine.

Wherea·s 86% of the rats se-

lected the PTZ lever after cocaine, 75% selected the PTZ
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TABLE 7.

Antagonism Tests with Diazepam and Chlordiazepoxide
After Their Chronic Administration.l

Drug

%

Dose
(mg/kg)

SOLVENT

Selecting PTZ Lever

Acute

..

Cnronic

6

100

100

67
17

67
33

30
20 ...

40

DIAZEPAM

2.5
10.0

6
6

CHLORDIAZEPOXIDE

2.5
10.0

10
10

1

3

20

Rats were injected with the appropriate dose of either diazepam, chlordiazepoxide or solvent. 30 min later PTZ (20 mg/kg) was injected. 15
min following the PTZ injection, animals were placed in their assigned
Skinner box and allowed to make a lever selection. The lever with which
ten responses were completed first was considered the selected lever.
2

3

Nwnber of rats tested.
Percent of rats selecting PTZ lever.

100
lever when haloperidol was injected before cocaine.

P.rior to

lever selection the rats emitted 0."8±0.33 responses with the
nonselected lever.

Response rate during the haloperidol plus

cocaine test session was significantly less (Duncan's Multiple Range Test, p<0.05) than response rate during the PTZ
and saline session preceding the test.
2.

R05-3663
R05-3663 (0.64-5 mg/kg) dose-dependently generalized

to the discriminative stimulus produced by PTZ (Table 3) . Diazepam (5 mg/kg) pretreatment antagonized the discriminative
stimulus produced by R05-3663 so that higher doses of this
drug were required to produce PTZ lever selection.

Whereas

100% of the rats injected with 5 mg/kg R05-3663 selected the
PTZ lever, none of the rats selected the PTZ lever when this
dose of R05-3663 was preceded by a 5 mg/kg diazepam injection.
However, 40 and 80% of the rats selected the PTZ lever when
injected with 10 and 20 mg/kg R05-3663, respectively 30 min
after diazepam (5 mg/kg) injection.

Prior to lever selec-

tion these rats emitted 2.6±1.60, 0."8±0.80 and 0.6+0.60
responses with the nonselected lever.

Response rates during

the diazepam plus R05-3663 (5 and 10 mg/kg) test session
were not significantly different (Duncan's Multiple Range
Test, p>0.05 and F.d. f.2,9=3.95, p>0.05) from response rates
during the PTZ and saline sessions preceding these tests.
However, response rate during the diazepam plus ROS-3663
(20 mg/kg) test session was significantly less (Duncan's

101

Multiple Range Test, P<0.05) than response rate during the
saline session but not the PTZ session preceding this test.

3.

Yohimbine
Yohimbine (2.5 mg/kg) generalized to the PTZ discrim-

inative stimulus in six of twelve rats

(Table 3). Diazepam

(5 mg/kg) pretreatment antagonized the yohimbine discriminative stimulus in three out of four of these rats that selected the PTZ leger after yohimbine alone.
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TABLE 8.

Tests for Diazepam and Haloperidol Antagonism of the Discriminative Stimuli Produced by Cocaine, Yohimnine and R05-3663 in
Rats Trained to Discriminate Between Pentylenetetrazol (20 mg/kg)
and Salinel

4

Test Drug

COCAINE

Dose
(mg/kg)

Pretreatment
Time
· (Minutesr

N

2

% Selecting

Mean Response s
(+S.E.) on NonSelected Lever
Before Lever Se~

P~Z t~v~i

1~ctiori ·

20

15

7

86

DIAZEPAM

5

30

6

0

DIAZEPAM

5

45-90

20

15-60

6

17

2. 3+1.43

HALOPERIOOL

0.16

75

5

0

0.40+0.4

HALOPERIDOL

0.16

75

20

15

8

75

4

100

1.7+1.2
0

+
COCAINE

+
COCAINE

YOHIMBINE

0.75+

2.5

30

5

60

2.5

30

4

25

R05-3663

5

30

6

100

1. 2+0 .80

DIAZEPAM

5

60

5

30

5

0

2 .6+1.60

10

30

5

40

0.8+0.80

20

30

5 ..

80

0.6+0.60

DIAZEPAM

0

+
YOHIMBINE

1+1.0

+
R05-3663

1

Following injection of the test drug the rats were placed in their
assigned Skinner box and allowed to make a lever selection. The lever
with which ten responses were completed first was considered the selected
lever.
2

Number of rats tested.

3% of rats selecting the PTZ lever.
4Responses (Mean±.S . E.) emitted with nonselected lever before lever
selection.
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TABLE 9.

Response Rates During Tests for Diazepam and Haloperidol Antagonism of the Discriminative Stimuli Produced by Cocaine and
R05-3663 in Rats Trained to Discriminate Between Pentylenetetrazol and Saline

Respons~s/10

Test
1
Drug

Dose
(m:J/kg)

Pretreatment
Time
2
(Minutes) . ·N

COCAINE

20

DIAZEPAM
+
COCAINE

5

45-90

20

15-60

15

Hin

3

Mean+S.E.
PTZ ·

Saline ··

3
%

S.E.+S.E.

Test
Drug

%

%

PTZ ·

Saline

7

843+38

991+74

767+77

93+12

82+13

6

553+88

658+87

223+93

42+19

33+15

HALOPERIDOL
0.16
+
COCAINE
20

15

8

500+70

820+99

315+55

83+24

40+8

R05-3663

5

30

6

396+64

587+140 370+67

92+96

69+10

DIAZEPAM
+
R05-3663

5

60

5
10
20

30
30
30

5
5
5

385+98 848+115 563+35 206+87
605+103 850+94 450+106 72+9
628+88 900+35 303+162 50+23

4

75

70+10
51+10
23+17

1

Test drugs were administered intraperitoneally. Following pretreatment
the rats were placed in their assigned Skinner box and allowed to respond with the levers for 10 min.
2

Number of rats tested.

3

Total responses (Mean+S.E.) emitted during the 10 min session following
pretreatment with the test drug and during the preceding pentylenetetrazol (20 mg/kg) and saline session.
4

values were obtained by dividing the total number of responses emitted
following test pretreatment by the total number of resonses during the
precedi.ng pentylenetetrazol ( 20 mg/kg) and saline sessions.
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DISCUSSION

Acquisition of PTZ-Saline Discrimination
A number of drugs are known to function as discriminative
stimuli which reliably control operant behavior (for reviews
see Schuster and Balster, 1977; Lal, 1977; Colpaert and Rosecrans, 1978).

Usually in these experiments laboratory ani-

mals are trained to emit one response when treated with a drug
and an alternate response when treated with the drug vehicle,
another dose of the same drug or a different drug.

When ac-

quisition of such response differentiation is reliably established, the drug is said to produce a discriminative stimulus
which controls the differential response - emission in the
trained subjects.
The present

experi~ent

demonstrates that rats can learn

to reliably discriminate between the effect of PTZ (20 mg/kg)
and saline.

A mean of 30 sessions was required for the rats

to reach the discrimination criterion.

A similar number of

trials to reach a similar criterion was previously reported
for many other psychoactive drugs (Weissman, 1978).

As was

the case with other drugs (Lal, 1976; 1977; Shearman et al.,
1978) the discriminative stimulus produced by PTZ was dosedependent.
Previously PTZ was reported to produce state-dependent
learning (Overton, 1966, 1973; Kurtz and Palfai, 1973).
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Anxioqenic Property of PTZ as a Discriminative Stimulus
1.

Time Course of PTZ Discrimination
In addition to its anxiogenic action, PTZ has also

been reported to produce hallucinations in man (Rodin, 1958;
Winter and Wallach, 1969).

However, whereas the anxiogenic

effect of PTZ diminishes soon after injection of PTZ is discontinued the hallucinations persist for up to 24 h after PTZ
injection. In order to test the hypothesis that the discriminative stimulus produced by PTZ in the rat was related to
its anxiogenic action and not its hallucinatory effect, discrimination of PTZ was tested at various times after injection of the drug.
Pharmacokinetic studies of PTZ in rats show that 70-95%
of this drug appears in the urine within 24 h
1971; Vohland and Koransky, 1972).

(Rowles et al.,

The cerebrospinal fluid

and plasma half-life of a 20 mg/kg PTZ injection in cats has
been reported to be approximately one hour (McMillen and
Isaac, 1978).
In the present study the discrimination of PTZ diminished
as the reported tissue levels of this drug decreased.

A sig-

nificant percentage of the rats no longer selected the PTZ
lever when the reported blood levels of PTZ were significantly decreased. These data support the hypothesis that the discriminative stimulus produced in the rat is related to its
anxiogenic property and not its hallucinatory effect.
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2.

Generalization Tests with Other Anxiogenics
To test the hypothesis that the discriminative stim-

ulus produced by PTZ in the rat was related to its anxiogenic
action in man (Rodin, 1958; Rodin and Calhoun, 1970; Winter
and Wallach, 1969), other anxiogenic stimulants were tested
for generalization to the PTZ discriminative stimulus.
Cocaine has been well recognized to induce anxiety in man
(Cohen, 1975; Siegel, 1977; Wesson and Smith, 1977).

Dose-

dependent generalization by cocaine to the PTZ discriminative
stimulus supports the hypothesis that the discriminative stimulus property of PTZ in the rat is related to its anxiogenic
action in man.

Additional support for this was provided by

the finding that the anxiolytic drug, diazepam, antagonized
the cocaine discriminative stimulus.

Whereas the nonanxiolyt-

ic drug, haloperidol, did not antagonize the cocaine discriminative stimulus.
In addition to its anxiogenic action, however, cocaine
is also a psychomotor stimulant.

In order to determine that

psychomotor stimulation was not the basis of the cocaine generalization to PTZ, nonanxiogenic psychomotor stimulants were
tested for generalization to PTZ.

Neither d-amphetamine,

methylphenidate nor caffeine generalized to the PTZ discriminative stimulus suggesting that the psychomotor stimulant
property of cocaine was not the basis of its discrimination
to PTZ.
Several investigators (Holmberg and Gershon, 1961; Ingram,
1962; Gershon and Lang, 1962; Garfield et al., 1967) have
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reported the anxiety-like effects produced by yohimbine in
man .
to

Amobarbital was reported to reduce the anxiety response

yoh~mbine

while imipramine and epinephrine potentiated

this effect (Holmberg and Gershon, 1961).
In the present study, yohimbine partially generalized to
the discriminative stimulus property of PTZ.

Furthermore, di-

azepam antagonized the yohimbine discriminative stimulus in
those rats that perceived the yohimbine stimulus as similar
to the PTZ discriminative stimulus.

These data support the

hypothesis that the discriminative stimulus property of PTZ
in the rat is related to its anxiogenic action in man .
ROS-3663 (l,3-dihydro-5-methyl-2H-l,4 benzodiazepin-2-one)
is structurally related to the anxiolytic drug, diazepan
(Schlosser and Franco, 1979).

However, unlike diazepam,

ROS-3663 does not bind to benzodiazepine receptors

(Speth et

al., 1979); O'Brien and Spirt, 1980) and antagonizes the effect of diazepam (Schlosser and Franco, 1979).

Because the

action of ROS-3663 is opposite to that of anxiolytic benzodiazepines this compound might be expected to be anxiogenic.
Recently, O'Brien and Spirt (1980) speculated that if
the anxiolytic action of benzodiazepines were considered to
be mediated through an antagonistic action then a molecule
structurally similar to ROS-3663 could exist in brain to
function as an endogenous anxiety producing

li~and.

In the

present study, ROS-3663 dose-dependently generalized to the
PTZ discriminative stimulus.

Furthermore, the discriminative

stimulus strength of ROS-3663 was attenuated by diazepam.
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These data provide behavioral evidence that ROS-3663 may
structurally resemble a naturally occurring anxiety-inducing
ligand · and support the hypothesis that the discriminative
stimulus produced by PTZ in the rat is related to the anxiogenic action in man.
It has been reported that patients poisoned with strychnine are extremely apprehensive and fearful of impending
death (Polson and Tattersall, 1969; Franz, 1975).

Strychnine

generalization to the discriminative stimulus produced by PTZ
supports the hypothesis that the discriminative stimulus
property of PTZ in the rat is related to its anxiolytic action in man.
In addition to the anxiogenic action of strychnine and
ROS-3663, however, these drugs are also convulsants.

In or-

der to determine that the convulsant action of strychnine
and ROS-3663 was not the basis of their generalization to
the PTZ discriminative stimulus several nonaxiogenic convulsant drugs were tested for generalization to the PTZ discriminative stimulus.
Bemegride, a central nervous system stimulant and convulsant drug like PTZ (Hahn, 1960) dose-dependently generalized to the PTZ discriminative stimulus.

This would suggest

that the convulsant action of strychnine and ROS-3663 was the
basis

of their generalization to the PTZ discriminative stim-

ulus and that the discriminative stimulus produced by PTZ was
related to its own convulsant action.

However, none of the
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other convulsant druqs tested, including picrotoxin, bicuculline, 3-mercaptoproprionic acid and nicotine, generalized to
the PTZ discriminative stimulus.
Also, gamma-hydroxybutyrate that produces a hypersynchronous EEG in the chick (Osuide, 1972), rat (Marcus et al.,
1967; Godschalk et al., 1976, 1977), cat (Winters and Spooner
1965), rabbit and man (Schneider et al., 1963), that is selectively antagonized by anti-petit rnal drugs

(Godschalk et al.,

1976) and has been compared to petit mal epilepsy (Winters
and Spooner, 1965; Snead et al., 1976; Godschalk et al., 1977),
did not generalize to the PTZ discriminative stimulus.

These

data suggest that the convulsant action of strychnine and
R05-3663 was probably not the basis of their generalization
to the PTZ discriminative stimulus and that a subconvulsant
or petit mal like brain state likely to be produced by these
drugs was not the basis of the discriminative stimulus produced by PTZ.

The finding that bemegride generalized to the

PTZ discriminative stimulus suggests that this drug may be
anxiogenic.

3.

Blockade of the PTZ Discriminative Stimulus by Anxio-

lytics
As another approach to test the hypothesis that the
discriminative stimulus produced by PTZ in the rat was related to its anxiogenic action in man, antagonism of the PTZ
discriminative stimulus by clinically effective anxiolytic
drugs was tested.

~10

Several benzodiazepine anxiolytics, barbiturate type anxiolytics as well as a propanediol carbamate anxiolytic effectively antagonized the PTZ discriminative stimulus in a
dose-dependent manner and in nonsedative doses.

In addition,

valproic acid, which was recently found to have anxiolytic
properties in a conflict test (Lal et al., 1979) also dosedependently antagonized the PTZ discriminative stimulus.
These data support the hypothesis that the discriminative
stimulus produced by PTZ in the rat is related to its anxiogenic action in man.
The potency of the various drugs effective in antagonizing the PTZ discriminative stimulus was highly correlated
with their effective doses in a widely accepted conflict test
used to measure anxiolytic activity (Figure 3) as well as
their clinically effective doses (Figure 4).

These data also

support the hypothesis that the discriminative stimulus
property of PTZ in the rat was related to its anxiogenic action in man.
In addition to anxiolytic activity, however, all of the
drugs that antagonized the PTZ discriminative stimulus are
also central nervous system depressants.

Several investi-

gators (Warner, 1965; Goldberg et al., 1967; Margules and
Stein, 1969; Stein et al., 1975; Cook and Sepinwall, 1975)
have reported that tolerance develops only to the depressant
action benzodiazepines.

Therefore, lack of tolerance develop-

ment to other actions of these drugs in experimental animals
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Figure 3.

Correlation between the effective dose of anxiolytic drugs in antagonnzing the anxiogenic qiscriminative st.irrulus of PTZ and their effective
doses in the ronflict test.
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has often been employed as a tool to identify pharmacological
actions for their predictive value for clinical efficacy
(Fielding and Lal, 1979; Lippa et al., 1979).

Because benzo-

diazepines have been the most widely studied anxiolytic drugs
with respect to tolerance development to their anxiolytic actions, it was investigated whether tolerance would not develop to two prototype benzodiazepines, chlordiazepoxide and
diazepam, in antagonism of the PTZ discriminative stimulus.
It was hypothesized that if the antagonistic property of these
benzodiazepines in the PTZ discrimination paradigm was related
to their anxiolytic action tolerance would not develop.

Pre-

viously, lack of tolerance development to the prevention of
PTZ-induced convulsions by diazepam was reported (Fuxe et al.,
1975; Juhasz and Dairman, 1977; Lippa and Regan, 1977).
The ability of either diazepam or chlordiazepoxide to antagonize the PTZ discriminative stimulus was not affected by
their chronic administration even though this treatment was
more than sufficient (Cook and Sepinwall, 1975; Goldberg
et al., 1967; Margules and Stein, 1968; Stein et al., 1975)
to produce tolerance to the depressant action of these drugs.
The present data are consistent with previous findings (Fuxe
et al., 1975; Jahasz and Dairman, 1977; Lippa and Regan,
1977) that show lack of tolerance development to prevention
of PTZ induced convulsions by diazepam.

Because tolerance

develops to the depressant but not anxiolytic action of benzodiazepines these data support the hypothesis that antagonism

of the PTZ discriminative stimulus by these drugs is related
to their anxiolytic action.
A~ditional

data which supports the suggestion that an-

tagonism of the PTZ discriminative stimulus was related to
anxiolytic action and not to the central nervous system depressant activity of these drugs was provided through antagonism tests with nonanxiolytic central nervous system depressants.

Etomidate is a nonbarbiturate hypnotic which is used

for the induction of anesthesia because of its short duration
of action (Jannsen et al., 1975).

The anxiolytic action of

etomidate has not been reported to date.

Although ethanol is

widely considered an anxiolytic, the anti-anxiety effect of
this drug has not been clearly demonstrated (Sepinwall and
Cook, 1978) •

Whereas morphine is known to alleviate anxiety

during opiate withdrawal (Redmond, 1979) it does not relieve
anxiety in opiate free individuals.

Chlorpromazine and hal-

operidol, useful in the treatment of psychoses, do not decrease

anxiety (Rickels et al., 1979).

None of these central nervous system depressants were
effective in antagonizing the discriminative stimulus produced by PTZ.

These data indicate that drugs that depress

the central nervous system but do not possess anxiolytic activity do not antagonize the PTZ discriminative stimulus.
Therefore these data support the hypothesis that the discriminative stimulus produced by PTZ in the rat is related
to its anxiogenic action.
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In addition to their anxiolytic and depressant actions,
all of the drugs that were effective in antagonizing the PTZ
discriminative stimulus are also effective against PTZ convulsions (Childress and Gluckman, 1964; Banziger, 1965;
Swingard and Castellion, 1966; Ludwig and Potterfield, 1971;
Dren et al., 1978; Lippa et al., 1979).

Based upon these

data, the finding that tolerance does not develop to diazepam
in antagonizing PTZ convulsions (Lippa and Regan, 1977) as
well as other considerations (Lippa et al., 1979), it has
been suggested that the ability of drugs to prevent or antagonize or prevent PTZ convulsions may reflect their anxiolytic
property (Hill and Tedeschi, 1971; Lippa and Regan, 1977;
Lippa et al., 1979).
Therefore, to test the hypothesis that antagonism of the
PTZ discriminative stimulus by these drugs was not related to
their anticonvulsant action, antagonism of the PTZ discriminative stimulus with anticonvulsants that lack clinical anxiolytic actions was tested.
Trimethadione and ethosuxirnide are known to protect laboratory animals against PTZ produced convulsions (Everett and
Richards, 1944; Toman and Goodman, 1948, Swinyard and
Castellion, 1966; Woodbury and Fingl, 1975).

These drugs are

effective in the treatment of petit-mal epilepsy (Woodbury
and Fingl, 1975) but not in the treatment of anxiety.

In the

present experiment neither trimethadione nor ethosuximide antagonized the discriminative stimulus produced by PTZ.
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Etomidate like trimethadione and ethosuximide, is known
to protect mice and rats against the convulsant action of PTZ
(Desmedt et al., 1976).

However, etomidate also did not an-

tagonize the PTZ discriminative stimulus.
Unlike trimethadione, ethosuximide and etomidate, diphenylhydantoin is an anticonvulsant which is ineffective in
petit mal epilepsy (Woodbury and Fingl, 1975) and does not
protect against pentylenetetrazol-induced convulsions (Everett
and Richards, 1944; Toman and Goodman, 1948; Swinyard and
Castellion, 1966) •

Diphenylhydantoin did not block the dis-

criminative stimulus produced by pentylenetetrazol.
There is a high correlation (R=0.95; p < 0.05) between the
potency of drugs effective in antagonizing the PTZ discriminative stimulus and their effective doses against PTZ-induced
convulsions (Figure 5).

However, whereas all drugs that an-

tagonize the PTZ discriminative stimulus prevent PTZ convulsions not all drugs that are effective against PTZ convulsions antagonize the PTZ discriminative stimulus.

These data

suggest that the anticonvulsant action of the drugs effective in antagonizing the PTZ discriminative stimulus is not
the property that is responsible for this effect.

These data

also suggest that the mechanism of action of the PTZ in producing convulsions is different from that underlying its mechanism for producing a discriminative stimulus.

Furthermore

these data suggest that antagonism of the PTZ discriminative
stimulus is a better measure of anxiolytic activity than is
antagonism of PTZ seizures.
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Neurochemical Correlates of the Anxioaenic Discriminative
Stimulus Property of PTZ
The exact neurochemical basis for anxiety is unknown.
However, it is possible that some indication of this may be
obtained from the postulated mechanism of action of anxiolytic drugs with the assumption that the neurochemical basis
for anxiety is opposite to that for the anti-anxiety action
of anxiolytic drugs.
Benzodiazepines are the most effective and thus most
widely prescribed drugs for the treatment of anxiety (Howard
and Pollard, 1977).

Also, this class of anxi9lytics has been

the most extensively studied with respect to their mechanism
of action (Costa and Greengard, 1975; Sepinwall and Cook,
1978; Koe, 1979).

In the present study, it was hypothesized that the neurochemical basis of the anxiogenic discriminative stimulus property of PTZ was opposite to that of the postulated neurochemical mechanism(s) responsible for the anxiolytic action
of benzodiazepines.

To test this hypothesis, drugs known to

have effects opposite to those of benzodiazepines on the neurotransmitter systems postulated to mediate the anxiolytic
action of benzodiazepines and drugs known to have a similar
effect as benzodiazepines on these neurotransmitter systems
were tested for generalization to and antagonism of the anxiogenic discriminative stimulus property of PTZ.
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1.

Garruna-aminobutyric Acid (GABA)
A functionally significant interaction between benzo-

diazep~nes

and brain gamma-aminobutyric acid (GABA) became

apparent from a variety of neurochemical (for reviews see
Costa et al., 1978, Costa and Guidotti, 1979) and neurophysiological (for review see Haefly, 1978) experiments.

However,

the pharmacological significance of such an inteiaction is
unclear.

Whereas the anticonvulsant, sedative, and muscle

relaxant actions of benzodiazepines seem to be related to GABAergic mechanisms

(Cook and Sepinwall, 1975; Lippa- et al.,

1979), a similar relationship for the anxiolytic action of
benzodiazepines is not clear.
To measure anxiolytic actions of drugs in experimental
animals, one test that is considered quite specific is the
conflict paradigm where reduction of response suppression by
"confliotful" stimuli is measured (Lippa' et al., 1979, Sepinwall and Cook, 1978) .

Inthis test, benzodiazepines are

known to show high potency and efficacy in nonsedative doses.
Therefore, the conflict model has been used to evaluate various neurochemical hypothesis for anxiolytic activity.

Cook

and Sepinwall (1975) reported that the GABA-T inhibitor, aminooxyacetic acid (AOAA), was without anti-conflict activity
alone and did not potentiate the anticonflict effect of diazepam.

Tye et al.

conflict effect.

(19_79) also reported that AOAA lacked antiThese data might suggest that alteration of

brain GABA is not related to anti-anxiety action.

However,

i-20

recent studies of Iadrola and Gale (1979,a,b) show that the
neuroanatomical sites of action of this GABA-T inhibitor is
not appropriate for anxiolytic activity.

First of all this

drug elevates brain GABA outside of nerve terminals.

In-

creasing the concentrations of GABA at these sites may actually inhibit neuronal GABA release because of its action on presynaptic autoreceptors.

In addition, the elevation of GABA

by AOAA is more pronounced in extrapyramidal areas.

The

GABA-T inhibitor, valproic acid, on the other hand, increases
brain GABA levels predominantly within nerve terminals and
in

brai~

sites in the limbic areas (Iadrola and Gale, 1979a,b).

Therefore, the lack of anxiolytic action by some GABA-T inhibitors may be due to the inappropriate site of their action.
Valproic acid's efficacy as an anxiolytic drug may be due to
an action at more appropriate sites.
Sullivan et al.

(1978) and Cook and Sepinwall (1979)

systemically administered the GABA receptor agonists muscimol and 4,5,6,7-tetrahydroisoxazolo (5, 4-c) pyridin-3-ol
(THIP) to examine their effect on conflict behavior.
as muscimol was weakly active, THIP was inactive.

Where-

Neither

muscimol nor THIP potentiated the anticonflict effect of
benzodiazepines in this test.

However, several investigators

(Baraldi et al., 1979; Maggi and Enna, 1979; Enna et al.,
1979) have reported that muscimol does not penetrate into
the brain after systemic administration.

This evidence may

explain the lack of anticonflict activity of muscimol and
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and its structural analogue, THIP.

Recently, Guidotti (per-

sonal communication) injected muscimol and THIP

intraventricu~

larly and reported that both of these drugs produced anticonflict activity in

rats~

Earlier data which suggested that the anticonflict activity of benzodiazepines might be -mediated oy GABA were provided by Stein et al.

ll975) and Zakusov et· al.

investigators reported that the

anti~conflict

(1977). These

activity of

benzodiazepines was reduced by the GABA antagonists picrotoxin, bicuculline or thiosemicarbizide.
Therefore, using the conflict model much data has been
generated to suggest that th.e anxiolytic action of benzodiaze..pines may be mediated by enhancing GABA activity.

It may be

hypothesized then, that anxiety is due to a deficit in GABA
neuronal function.
In order to test the hypothesis that decreased GABA neuronal activity was the neurochemical basis for the anxiogenic
discriminative stimulus property of PTZ, generalization to
the PTZ discriminative stimulus with GABA antagonistic drugs
and antagonism of the PTZ discriminative stimulus with GABA
minetic drugs was tested.
Picrotoxin and bicuculline were used as antagonists of
tne postsynaptic inh1Bitory action of GABA (Curtis and
Johnson, 1974).

Whereas bicuculline acts at the receptor

sites (Curtis and Johnson, 1974) , picrotoxin seems to act at
chloride channels (Olsen· et ·a1., 1978a,b).

Schecter and

122

Tranier (1977) found that GABA-transaminase inhibitors prolong the onset of seizure and death following picrctoxin but
not following bicucuclline.

Other differences between picro-

toxin and bicuculline have been reported with respect to
GABA-receptor sensitivity (Krnjevic, 1974), blockade of GABA
binding to brain receptors (Zukin et al., 1974), stimulation
3
of [ H]-GABA release from brain tissue (Collins, 1973; Johnston and Mitchell, 1971), alteration of specific

r3H]-diaze-

pam binding ih cortical membranes (Tallman et al., 1978) and
.
-induction of epileptic spikes following topical application
and systemic injection (Edmonds and Bellin, 1976) .
Whereas, picrotoxin partially generalized to the PTZ
discriminative stimulus, bicucuclline did not generalize.
Therefore, these data do not conclusively support the hypothesis that the anxiogenic discriminative stimulus property
of PTZ is related to decreased GABA neuronal activity.
3-Mercaptopropionic acid is

a

convulsant drug that acts

by inhibiting glutamate decarboxylase and producing a subsequent decrease in the concentration of brain GABA (Lamar,
1970).

Like picrotoxin, 3-mercaptopropionic acid partially

generalized to the PTZ discriminative stimulus.

Therefore

these data although suggestive do not fully support the hypothesis that decreased GABA function is the basis of the
anxiogenic discriminative stimulus property of PTZ.
R0-3663 is a convulsant benzodiazepine that selectively
antagonizes the effect of GABA at spinal and peripheral neuronal sites (Schlosser and Franco, 1979).

In addition, this
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drug has been reix>rted to inhibit the GABA enhancement of
3
H-diazepam binding (O'Brien and Spirt, 1980) and binding of
the GABA receptor antagonist, alpha picrotoxiu in LeebLundberg et al.

(1979).

ROS-3663 dose-dependently general-

ized to the PTZ discriminative stimulus.

Furthermore, the

discriminative stimulus strength of ROS-3663 was attenuated
by diazepam.

Although the exact neurochemical basis through

which ROS-3663 produces its discriminative stimulus cannot be
determined at present, these data support the hypothesis that
decreased GABA neuronal activity is the neurochemical basis
of the PTZ discriminative stimulus.
Based upon the differential antagonism of iontophoretically applied etomidate and GABA by bicuculline but not by
strychnine, Evans and Hill

(1978) proposed etomidate to be a

central GABA-mimetic drug.

Etomidate did not antagonize the

PTZ discriminative stimulus.

The inability of etomidate to

antagonize the PTZ discriminative stimulus does not support
the hypothesis that discriminative stimulus is related to a
deficit in brain GABA function.

It should also be noted,

however, that whereas etomidate was ineffective in blocking
the PTZ discriminative stimulus, other sedative hypnotics
such as pentobarbital and phenobarbital which also possess
anxiolytic activity were effective antagonists of the pentylenetetrazol discriminative stimulus.
At higher dose levels, ganuna-hydroxybutyrate acts like
a GABA agonist in the central nervous system (Anden and
Stock, 1973; Roth and Nowycky, 1977).

Pretreatment of the
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animals with gaITlll1a-hydroxybutyrate did not antagonize the
discriminative stimulus produced by PTZ also suggesting that
the

PT~

discriminative stimulus is not related to decreased

GABA neuronal activity.
Gamma-acetylentic GABA (GAG) and gamma-vinyl-GABA (GAG)
are inhibitors of GABA-T which increase the brain GABA levels
of mice and rats

(Jung et al., 1977a; Jung et al., 1977b) and

protect animals against seizures induced by audiogenic stimulation, strychnine, isoniazid, thiosemicarbizide and electric
shock (Schecter et al., 1977a,b), but not picrotoxin, bicuculline nor PTZ (Schecter et al., 1977a,b) antagonized the
discriminative stimulus produced by PTZ.

Thus these data do

not support the hypothesis that the PTZ discriminative stimulus is related to a deficit of brain GABAergic functioning.
However, it may be premature to consider the above data
as going against the hypothesis that the anxiogenic discriminative stimulus property of PTZ is related to decreased GABA
neuronal activity.

Recently, Iadrola and Gale (1979a,b) have

shown that the GABA-T inhibitors GAG and GVG increase brain
GABA primarily in nonsynaptosomal sites such as glia.
In order to overcome these shortcomings the indirectly
acting GABA mimetic drug, valproic acid, was tested for antagonism of the PTZ discriminative stimulus.

Although val-

proic acid inhibits GABA-T (Godin et al., 1969, Simler et al . ,
1973; Fowler et al., 1975), enzyme-kinetic studies show that
it increases brain GABA levels primarily by causins an accumulation of succinic semialdehyde through inhibition of
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succinic semialdehyde dehydrogenase (Van der Lann et al.,
1979).

The succinic semialdehyde in turn blocks the conver-

sion of GABA to succinic semialdehyde through product inhibition.

These actions are preferentially localized within

the nerve terminal
~_!;:al.,

1979).

(Van der Lann et al., 1979; Bruinvels

In addition, whereas other GABA-T inhibitors

ca.use GABA elevation primarily in the compartments outside of
nerve terminals, GABA elevation produced by valproic acid is
primarily located ih nerve terminals (Iadrola and Gale, 1979;
Sarhan and Seilar, 1979).

Valproic acid has also been re-

ported to inhibit the reuptake of GABA into nerve terminals
{ftarvey, 1976).

Valproic acid dose-dependently antagonized

the anxiogenic discriminative stimulus produced by PTZ. These
data support the hypothesis that a deficit in GABA neuronal
activity is the neurochemical basis of the anxiogenic discriminative stimulus property of PTZ.

These data also sug-

gest that valproic acid may be a clinically effective anxiolytic drug and that deficits i.n GABA functioning are important for anxiety.

Furthermore these data suggest that

antagonism of the PTZ discriminative stimulus by benzodiazepines, and thus their anxiolytic action might be related to
thei.r property of enhancing GABA transmission.
2.

Glycine
A significant correlation between the ability of a

series of J5enzodiazepines to reduce

3

H-strychnine binding

to glycine receptors and their clinical effects led to the
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proposal that these drugs might produce their muscle relaxant and anti-anxiety action by mimicking glycine at its receptor

~ites

(Young et al., 1974; Snyder and Enna, 1975).

However, when Cook and Sepinwall (1975), using the data of
Young et al.

(1974), compared the

3

H-strychnine displacement

potency of ten benzodiazepines with their anticonflict patency, they did not £ind a significant correlation.

Because

there was a significant correlation between anticonflict potency and potency in a human bioassay it was concluded that
the affinity of benzodiazepines £or the glycine receptor was
not correlated with anxiolytic activity.
et al.

Furthermore, Stein

(1975) reported that although strychnine reduced the

anticon£lict effect of oxazepam it also depressed unpunished
responding suggesting that this effect was nonselective.
In order to test the hypothesis that decreased glycinergic activity was the neurochemical basis of the anxiogenic
discriminative stimulus property of PTZ, the glycine antagonist (Curtis and Johnson, 1974) strychnine, was tested for
generalization to the PTZ discriminative stimulus.
Although not completely strychnine generalized to the
PTZ discriminative stimulus thus supporting the hypothesis
that decreased glycinergic activity was the basis £or the
anxiogenic discriminative stimulus property of PTZ.
McDonald and Barker (1977) reported that whereas PTZ
antagonized the post-synaptic inhibitory responses to GABA
in a mammalian tissue culture system it did not affect glycine responses.

Therefore, unless i t is de:rronstrated that
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PTZ antagonizes glycine the hypothesis that the neurochemical
basis of the PTZ discriminative stimulus is due to decreased
glycin~rgic

activity might not be tenable.

There was consid-

erable evidence presented earlier that suggests that · the discriminative stimulus produced by PTZ was related to decreased
GABA Neuronal activity.

Because both GABA and glycine are

inhibitory neurotransmitters i t may be suggested that interference with either of these inhibitory systems produces a
discriminative stimulus that provides the basis for the common discriminative stimulus properties of these drugs.
3.

Phosphodiesterase Inhibition
Based upon

a

significant correlation between the in

vitro potency of several drugs in inhibiting phosphodiesterase and their potency in the thirsty rat conflict test, Beer
et al.

(1972) proposed that the anxiolytic activity of drugs

may be related to their ability to inhibit this enzyme.
support of this hypothesis, Weinryb et al.

In

(1975), found that

a series of substituted pyrazoF--(3, 4b) -pyr idines that were
potent inhibitors of phosphodiesterase had significant anticonflict activity.

However, Morrison (1969) and Cook and

Sepinwall (1975) did not find significant anticonflict effeet of phosphodiesterase inhibitors in a lever press conflict test.

Furthermore, Collins et al.

(1976) reported

that the potent phosphodiesterase inhibitor, SQ 65,396 was
without anxiolytic effect compared to diazepam and placebo
in psychoneurotic patients.
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In order to test the hypothesis that the ability of benzodiazepines to antagonize the discriminative stimulus property pf PTZ was not related to their ability to inhibit
phosphodiesterase, antagonism of the PTZ discriminative stimulus with the phosphodiesterase inhibitor, caffeine, was
tested.
Caffeine did not antagonize the anxiogenic discriminative
stimulus property of PTZ.

This finding supports the hypothe-

sis that the ability of benzodiazepines to antagonize the PTZ
discriminative stimulus was not related to their ability to
inhibit phosphodiesterase.

These data also support previous

work (Morrison 1969; Cook and Sepinwall, 1975; Collins et al.,
1976) that suggests that the anxiolytic action of benzodiazepines is not related to their inhibition of phosphodiesterase.
4.

Acetylcholine
There is no clear correlation between the effect of

benzodiazepines on cholinergic function and their antianxiety action.

Benzodiazepines were reported to increase

rat brain acetylcholine levels (Consolo et al., 1975).

The

functional significance of this, however, is unclear as there
was no correlation between the muscle relaxant or anti-PTZ
of the benzodiazepines and their effect on acetylcholine even
though PTZ has been reported to cause a decrease in rat brain
acetylcholine (Giarrnan and Pepeu, 1962; Beani et al . , 1969;
Longoni et al., 1974; Consolo et al., 1975) by causing a massive release of this neurotransmitter.

In one behavioral
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study, Soubrie et al.

(1976) reported that diazepam antago-

nized the hyperactivity elicited by anticholinergics in mice.
This effect was blocked by picrotoxin implicating the involvement of GABA mechanism for this action of diazepam.
In donflict tests, cholinergic agonists (Morrison, 1969)
or antagonists (Hanson et al., 1970; Miczek, 1973) were without significant anticonflict effect.

In order to test the

hypothesis that the anxiogenic discriminative stimulus property of PTZ was related to its effect on cholinergic function, generalization to and antagonism of the PTZ discriminative stimulus with cholinergic agonistic and antagonists
was tested.
None of the cholinergic drugs tested either generalized
to or antagonized the PTZ discriminative stimulus.

These

data do not support the hypothesis that the neurochemical
basis of the anxiogenic discriminative stimulus property of
PTZ was related to its action on cholinergic function.

Fur-

thermore , these data suggest that the ability of benzodiazepines to antagonize the PTZ discriminative stimulus was not
related to their affect on cholinergic function.
5.

Serotonin
There is considerable biochemical (Stein et al . ,

1975) and behavioral (for reviews see Sepinwall and Cook,
1978; Koe, 1979) evidence obtained from animal experiments
that the benzodiazepines may exert their anti-anxiety action
by decreasing serotonin activity .

130

Stein et al.

(1975)

reported that whereas tolerance de-

veloped to the depressant action and effect of benzodiazepines on decreasing norepinephrine turnover, tolerance did
not develop to their anticonflict effect or their effect of
decreasing serotonin turnover.

Using conflict paradigms it

has been demonstrated that reduction serotonin activity by
inhibition serotonin synthesis (Robichaud and Sledge, 1969;
Geller and Blum, 1970; Schoenfeld, 1976), blockade of serotonin receptors (Graef£ and Schoenfeld, 1970; Graeff, 1974;
Stein et al., 1973; Winter, 1972) or destruction of serotonin
nerve terminals (Stein et al., 1975) produces significant
anticonflict effects.

However, there have been some reports

(Winter, 1972; Blakely and Parker, 1973; Cook and Sepinwall,
1975a) that show a lack of anticonflict effect of serotonin
antagonistic drugs.

Whereas serotonin antagonists are usual-

ly reported to have anticonflict effects, serotonin agonists
have been reported (Graeff and Schoenfeld, 1970; Winter,
1972; Geller et al., 1974) to significantly suppress conflict
behavior.
In order to test the hypothesis that the anxioqenic discriminative stimulus property of PTZ was related to an agonistic effect of this drug on serotonin function, generalization to the PTZ discriminative stimulus with serotonin agonists and antagonism of the PTZ discriminative stimulus with
serotonin antagonists was tested.
Neither of the serotonin agonists used in this study
(5-HTP and fluoxetine) generalized to the PTZ discriminate
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stimulus.

Furthermore, the serotonin receptor antagonist,

methysergide, did not antagonize the discriminative stimulus
proper~y

of PTZ.

These data do not support the hypothesis

that the neurochemical basis of the anxiogenic discriminative
stimulus property of PTZ was related to an agonistic effect
on serotonin function.

Furthermore, these data suggest that

the ability of benzodiazepines to antagonize the PTZ discriminative stimulus is not related to their ability to decrease
serotonin transmission.
It is interesting that serotonin antagonists are not
clinically effective anxiolytics therefore reduction of serotonin function by these drugs might not be the neurochemical
basis for their anxiolytic action as suggested by other animal studies.
6.

Catecholamines
Benzodiazepines are known to decrease the turnover

of both norepinephrine and dopamine (for review see Koe,
1979).

There is no clear evidence, however, that this effect

is related to the anxiolytic activity of these drugs.
et al.

Fuxe

(1975) reported that diazepam antagonized increases

in norepinephrine turnover produced by stress or injection of
the anxiogenic drug yohirnbine.

Gray (1976) reported similar

effects for chlordiazepoxide as well as norepinephrine synthesis inhibitors or lesions of the dorsal noradrenergic
bundle against stress.

Lader (1974) reviewed evidence for

the involvement of catecholamines in anxiety and more recently
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Redmond (1979) summarized considerable evidence for a role
of norepinephrine in anxiety.
I~

activation of catecholaminergic system causes anxiety

then drugs effective in decreasing catecholaminergic transmission should decrease anxiety.

The beta-adrenergic recep-

tor blockers, propranolol and oxprenolol have been reported
to have anxiolytic activity (Jefferson, 1974; Krishman, 1976).
However, whereas standard anxiolytics are effective against
both the somatic and psychic components of anxiety, these
drugs appear to be effective only against the somatic anxiety.
In the conflict test, Sepinwall et al.

(1973) reported pro-

pranolol to be without significant anticonflict effect.
Recently, Kruse et al.

(1980) reported that the presyn-

aptic alpha-adrenergic agonist, clonidine, produced signif icant anticonflict activity in the rat.

Furthermore, this ef-

f ect was antagonized by the pre-synaptic alpha-receptor
blocker (Starke et al., 1975), yohimbine.

Several investi-

gators (Holmberg and Gershon, 1961; Ingram, 1962; Gershon
and Lang, 1962; Garfield et al., 1967) had previously reported that yohimbine produced anxiety in humans.
To test the hypothesis that the anxiogenic discriminative stimulus property of PTZ was related to an action of
increasing catecholaminergic transmission, catecholamine
agonists were tested for generalization to the PTZ discriminative stimulus and catecholamine antagonists were tested
for antagonism of the PTZ discriminative stimulus.

Of the

catecholamine agonists tested for generalization only cocaine
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significantly generalized to the PTZ discriminative stimulus.
The dopamine receptor agonist, apomorphine, as well as yohimbine partially generalized; however, a-amphetamine and
methylphenidate did not.

Propranolol that was previously re-

ported to generalize to the discriminative stimulus property
of cocaine (Silverman and Ho, 1977), did not generalize to
the PTZ discriminative stimulus.

These data leave it unclear

whether the anxiogenic discriminative stimulus property of
PTZ was related to an action of activating catecholaminergic
mechanisms.

However, when several catecholamine antagonists

including clonidine, aceperone, propranolol, haloperidol or
chlorpromazine were tested for antagonism of the PTZ discriminative stimulus they were found to be without effect.
Therefore, these data do not conclusively support the hypothesis that the anxiogenic discriminative stimulus prospects
of PTZ is related to an effect of increasing catecholaminergic activity.
7.

Endorphins
The effect of benzodiazepines on endorphins is still

being worked out.

Therefore, the possible involvement of

these newly discovered endogenous substances in mediating the
anxiolytic activity of benzodiazepines on anxiety remains to
be determined.

Some of the behavioral effects of benzodiaze-

pines, including their anticonflict effect, however, have
been reported to be antagonized by the narcotic antagonist,
naloxone (Billingsly and Kibena, 1978; Gylys et al., 1979).

--

Thesedata might suggest that anxiolytic activity is mediated
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by activation of endorphinergic systems.
To test the hypothesis that the anxiogenic discriminative stimulus property of PTZ was related to an antagonistic
effect on endorphin systems, generalization to the PTZ discriminative stimulus with naloxone was tested as was antagonism of the PTZ discriminative stimulus with morphine.

The

failure of naloxone to generalize to the PTZ discriminative
stimulus and the failure of morphine to antagonize this stimulus does not support the hypothesis that the anxiogenic discriminative stimulus property of PTZ is related to an antagonistic action on endorphin systems.
8.

Endogenous Benzodiazepine Receptor (Ligand(s)
The demonstration of saturable, high-affinity, ster-

eospecific benzodiazepine binding sites in the central nervous system (Squires and Braestrup, 1977; Mohler and Okada,
1977) suggested the presence of endogenous ligands capable
of regulating the neurophysiological processes subserved by
these receptors.

Several such substances have been sug-

gested as endogenous ligands for benzodiazepine receptors
(Colello et al., 1978; Karobath et al., 1978; Marangos et
al., 1978; Skolnick et al., 1978; Mohler et al., 1979;
Nixon and Wolf, 1979; Skolnick et al., 1979), however, their
potency is too weak to satisfy a neurotransmitter or neuromodulator role.
Although none of the candidates to date satisfy all the
criteria for an endogenous ligand of the benzodiazepine
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receptor, purines and nicotinamide do have benzodiazepine-like
properties in vivo.
Skolnick et al.

Despite the relatively low affinity,

(1979) reported that inosine produced a dose-

and time-related antagonism of PTZ-induced convulsions and
proposed that endogenously occurring purines such as inosine
could be naturally occurring ligands for benzodiazepine receptors.

Although the affinity of nicotinamide for the benzo-

diazepine receptor is approximately four to five fold lower
than affinlties reported for purines (Mohler

~t

al., 1979),

this naturally occurring substance has been reported to partially restore behavior suppressed by punishment in rats.
Marangos et al.

(1979) reported that pentylenetetrazol

inhibited 3 H-diazepam binding in vitro and suggested that PTZ
may exert pharmacological actions by an interaction with the
benzodiazepine receptor.

Based upon the antagonism of the

PTZ discriminative stimulus by benzodiazepines it is possible
that the anxiogenic discriminative stimulus property of PTZ
is related to its interaction with this receptor.

It is pos-

sible that PTZ may exert its angiogenic action by inhibiting
the binding of a naturally occurring anxiolytic ligand to
benzodiazepine receptors or mimicking the action of a naturally occurring anxiety-inducing ligand.
ROS-3663 is structurally related to diazepam, however,
unlike diazepam it does not bind to benzodiazepine receptors
(Speth ·et ·a 1., 1979; O'Brien and Spirt, 1980).

Furthermore,

whereas diazepam has GABAmimetic activity ROS-3663 antagonizes the effect of GABA (Schlosser and Franco, 1979; O'Brien
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and Spirt, 1980).

O'Brien and Spirt (1980) speculated that if

the anxiolytic action of benzodiazepines were considered to be
mediat~d

through an antagonistic action then a molecule struc-

turally similar to ROS-3663 could exist in brain to function
as an endogenous anxiety-inducing ligand.
ROS-3663 dose-dependently generalized to the PTZ discriminative stimulus.

Furthermore, the discriminative strength of

ROS-3663 was attenuated by diazepam.

These data provide be-

havioral evidence that ROS-3663 may structurally resemble a
naturally occurring anxiety-inducing ligand.

If this is the

case PTZ may act by a similar mechanism as this naturally occurring anxiety-inducing ligand.
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SUMMARY AND CONCLUSIONS
In summary, it was deITK)nstrated that laboratory rats can
learn to discriminate between a subconvulsive dose (20 mg/kg)
of PTZ and saline.

A mean of 30 training sessions were re-

quired for the animals to reach the discrimination criterion.
The discriminative stimulus produced by PTZ was dose- and
time-dependent.
The anxiogenic stimulants cocaine, ROS-3663 and strychnine generalized to the PTZ discriminative stimulus whereas
yohimbine partially generalized.

The discriminative stimu-

1 us produced by cocaine, ROS-3663 and yohimbine was antagonized by diazepam.

The discriminative stimulus produced by

cocaine was not antagonized by haloperidol.

The non-anxio-

genic psychomotor stimulants a-amphetamine, methylphenidate
and caffeine did not generalize to the PTZ discriminative
stimulus.

These data support the hypothesis that the dis-

criminative stimulus produced by PTZ in the rat is related
to its anxiogenic action in man.
Of the several convulsant drugs tested, only bemegride
significnatly generalized to the PTZ discriminative stimulus
whereas picrotoxin and 3-mercaptopropionic acid partially
generalized.

Bicuculline, nicotine or gamrna-hydroxybutyrate

did not generalize to the PTZ discriminative stimulus.

These

data suggest that the PTZ discriminative stimulus is probably
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not relate<l to a subconvulsant brain state likely to be produced by these drugs.
Tpe PTZ discriminative stimulus was dose-dependently antagonized by benzodiazepine-type, barbiturate-type and propanediol carbamate-type anxiolytics as well as valproic acid.
Because tolerance develops to the sedative but not anxiolytic
benzodiazepines, lack of tolerance development to diazepam
or chlordiazepoxide in antagonism of the PTZ discriminative
stimulus suggests that this property w&s related to their
anxiolytic action.
There was a significant correlation between the potency
of the drugs effective in antagonizing the PTZ discriminative stimulus and their effective doses in a conflict test
used to measure anxiolytic activity as well as their clinically effective doses.
The PTZ discriminative stimulus was not antagonized by
the nonanxiolytic anticonvulsants ethosuximide, etomidate,
trimethadone or diphenylhydantoin nor the nonanxiolytic central nervous system depressants morphine, ethanol, chlorprornazine, or haloperidol.

These data suggest that the PTZ

discriminative stimulus is not related to a subconvulsant
brain state or nonspecific central nervous system stimulation.
The GABA antagonist, ROS-3663, dose-dependently generalized to the PTZ discriminative stimulus, whereas picrotoxin
and 3-mercaptopropionic acid partially generalized.

The

GABAmimetic drug, valproic acid, antagonized the PTZ dis-
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crirninative stimulus.

These data suggest that the PTZ dis-

criminative stimulus might be mediated through decreased GABA
neuronal activity.

Because of the known GABA ·mimetic pro-

perty of benzodiazepines it was suggested that antagonism of
the PTZ discriminative stimulus by these drugs may be related
to their effect on GABA transmission.
The glycine antagonist, strychnine, generalized to the
PTZ discriminative stimulus suggesting the possible involvement of decreased glycinergic activity for the discriminative
stimulus property of PTZ.

However, in view of the consider-

able evidence for the involvement of GABA and the lack of effect of PTZ on glycine in vitro it was suggested that general
interference with inhibitory transmission -may generate a discriminative stimulus like that produced by PTZ.
Drugs affecting acetylcholine or serotonin systems did
not generalize to or antagonize the PTZ discriminative stimulus.

These data suggested that the PTZ discriminative

stimulus was not related to an effect on these neurotransmitter systems.
Cocaine generalized to the PTZ discriminative stimulus
whereas yohimbine and apomorphine partially generalized.
The PTZ discriminative stimulus was not blocked by drugs
with anti-catecholaminergic activity.

Therefore these data

do not support the involvement of catecholamine mechanisms
for the discriminative stimulus property of PTZ.
In view of the recent demonstration of benzodiazepine
receptors in brain, i t was suggested that PTZ may produce

141

its anxiogenic action by interacting with an unknown ligand
for the benzodiazepine receptor.

PTZ may either mimic a natur-

ally o?curring anxiety-inducing ligand or inhibit the action
of a naturally occurring anxiolytic ligand.
In conclusion the data presented in this dissertation
support the hypothesis that the discriminative stimulus property of PTZ in the rat is related to its anxiogenic action in
man.

It is suggested that the anxiogenic stimulus produced

by PTZ is related to deficits in GABA neuronal activity.
Tedeschi (1969) suggested that for animal tests to have
predictive value as models for a particular human condition,
they must fulfill the following criteria:
1.

Tests should be selective enough to differentiate

false positives, and to distinguish side effects from therapeutic activity.
2.

Tests should be sensitive enough to detect activity

of reference agents within a reasonable dose range.
3.

The relative potency of reference agents in the

animal test should compare with their relative potency in man.
4.

Tolerance should not develop to the measure presumed

to reflect therapeutic efficacy.
The PTZ-saline discrimination paradigm described in this
dissertation fulfills all of these criteria.

Therefore it

is suggested that this procedure may represent a new animal
model of anxiety that can be used to detect anxiolytic activity of new compounds.
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Currently, prevention of PTZ-induced seizures is used as
a screening test for anxiolytic drugs.

However, all of the

drugs that prevent these seizures are not anxiolytics.

To

date there have been no false positives in the PTZ-saline discrimination procedure.

All of the drugs that antagonize the

PTZ discriminative stimulus are clinically effective anxiolytics. Currently, there is no animal model to detect anxiogenic side effects of drugs; the PTZ-saline discrimination
may provide such a model.
In addition to these potential benefits for drug development, the PTZ-saline discrimination may be used to investigate the neurochemical mechanisms and behavioral factors related to anxiety as well as the mechanism of action of anxiolytic drugs.

It is the author's hope that the work reported

in this dissertation will contribute towards these ends.
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